{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:54:45Z","timestamp":1793199285520,"version":"4.5.0"},"reference-count":290,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82401623, 82503252 and 82573653"],"award-info":[{"award-number":["82401623, 82503252 and 82573653"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Henan Medical Science and Technique Foundation","award":["LHGJ20230239, LHGJ20250279 and SBGJ202402043"],"award-info":[{"award-number":["LHGJ20230239, LHGJ20250279 and SBGJ202402043"]}],"id":[{"id":"https:\/\/ror.org\/056cbez68","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Henan Provincial Natural Science Foundation","award":["242300421481 and 252300423196"],"award-info":[{"award-number":["242300421481 and 252300423196"]}]},{"name":"the Excellent Young Talents Program in Health and Health Technology Innovation for Mid-career Professionals in Henan Province","award":["YQRC2025009"],"award-info":[{"award-number":["YQRC2025009"]}]},{"name":"Henan Provincial Key Research and Development Special Project","award":["251111313300"],"award-info":[{"award-number":["251111313300"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02555-9","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T14:47:16Z","timestamp":1768920436000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Notch signaling in the tumor microenvironment: recent advances and targeted therapeutics"],"prefix":"10.1186","volume":"25","author":[{"given":"Di","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingdian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henan","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peidong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazhou","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhe","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongming","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuqiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"2555_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00280-x","volume":"5","author":"MZ Jin","year":"2020","unstructured":"Jin MZ, Jin WL. The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther. 2020;5:166.","journal-title":"Signal Transduct Target Ther"},{"key":"2555_CR2","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ccell.2023.01.010","volume":"41","author":"O Elhanani","year":"2023","unstructured":"Elhanani O, Ben-Uri R, Keren L. Spatial profiling technologies illuminate the tumor microenvironment. Cancer Cell. 2023;41:404\u201320.","journal-title":"Cancer Cell"},{"key":"2555_CR3","doi-asserted-by":"publisher","first-page":"216894","DOI":"10.1016\/j.canlet.2024.216894","volume":"591","author":"M El-Tanani","year":"2024","unstructured":"El-Tanani M, Rabbani SA, Babiker R, Rangraze I, Kapre S, Palakurthi SS, et al. Unraveling the tumor microenvironment: insights into cancer metastasis and therapeutic strategies. Cancer Lett. 2024;591:216894.","journal-title":"Cancer Lett"},{"key":"2555_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06654-8","volume":"9","author":"A Chakravarthy","year":"2018","unstructured":"Chakravarthy A, Khan L, Bensler NP, Bose P, De Carvalho DD. TGF-\u03b2-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nat Commun. 2018;9:4692.","journal-title":"Nat Commun"},{"key":"2555_CR5","doi-asserted-by":"publisher","first-page":"390","DOI":"10.2174\/0113892029300608240531111743","volume":"25","author":"Z Peng","year":"2024","unstructured":"Peng Z, Fang C, Tong Z, Rao Q, Ren Z. Crosstalk between cancer-associated fibroblasts and myeloid cells shapes the heterogeneous microenvironment of gastric cancer. Curr Genomics. 2024;25:390\u2013411.","journal-title":"Curr Genomics"},{"key":"2555_CR6","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.canlet.2019.11.009","volume":"470","author":"X Lei","year":"2020","unstructured":"Lei X, Lei Y, Li JK, Du WX, Li RG, Yang J, et al. Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy. Cancer Lett. 2020;470:126\u201333.","journal-title":"Cancer Lett"},{"key":"2555_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","volume":"30","author":"I Vitale","year":"2019","unstructured":"Vitale I, Manic G, Coussens LM, Kroemer G. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 2019;30:36\u201350.","journal-title":"Cell Metab"},{"key":"2555_CR8","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2174\/0113892029284920240212091903","volume":"25","author":"N Baqai","year":"2024","unstructured":"Baqai N, Amin R, Fatima T, Ahmed Z, Faiz N. Expression profiling of EMT transcriptional regulators ZEB1 and ZEB2 in different histopathological grades of oral squamous cell carcinoma patients. Curr Genomics. 2024;25:140\u201351.","journal-title":"Curr Genomics"},{"key":"2555_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-024-01364-2","volume":"57","author":"J Kim","year":"2025","unstructured":"Kim J, Park S, Kim J, Kim Y, Yoon HM, Rayhan BR, et al. Trogocytosis-mediated immune evasion in the tumor microenvironment. Exp Mol Med. 2025;57:1\u201312.","journal-title":"Exp Mol Med"},{"key":"2555_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221:107753.","journal-title":"Pharmacol Ther"},{"key":"2555_CR11","volume":"17","author":"SM Manohar","year":"2024","unstructured":"Manohar SM. At the crossroads of TNF \u03b1 signaling and cancer. Curr Mol Pharmacol. 2024;17:e060923220758.","journal-title":"Curr Mol Pharmacol"},{"key":"2555_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/cac2.12416","volume":"43","author":"A Goenka","year":"2023","unstructured":"Goenka A, Khan F, Verma B, Sinha P, Dmello CC, Jogalekar MP, et al. Tumor microenvironment signaling and therapeutics in cancer progression. Cancer Commun (Lond). 2023;43:525\u201361.","journal-title":"Cancer Commun (Lond)"},{"key":"2555_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.semcancer.2021.04.008","volume":"85","author":"A Ferreira","year":"2022","unstructured":"Ferreira A, Aster JC. Notch signaling in cancer: complexity and challenges on the path to clinical translation. Semin Cancer Biol. 2022;85:95\u2013106.","journal-title":"Semin Cancer Biol"},{"key":"2555_CR14","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1101\/gad.342287.120","volume":"34","author":"A Nandi","year":"2020","unstructured":"Nandi A, Chakrabarti R. The many facets of notch signaling in breast cancer: toward overcoming therapeutic resistance. Genes Dev. 2020;34:1422\u201338.","journal-title":"Genes Dev"},{"key":"2555_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ado8275","volume":"10","author":"Q Shen","year":"2024","unstructured":"Shen Q, Murakami K, Sotov V, Butler M, Ohashi PS, Reedijk M. Inhibition of notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer. Sci Adv. 2024;10:eado8275.","journal-title":"Sci Adv"},{"key":"2555_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01439-z","volume":"16","author":"X Li","year":"2023","unstructured":"Li X, Yan X, Wang Y, Kaur B, Han H, Yu J. The notch signaling pathway: a potential target for cancer immunotherapy. J Hematol Oncol. 2023;16:45.","journal-title":"J Hematol Oncol"},{"key":"2555_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ccell.2019.08.003","volume":"36","author":"R Jackstadt","year":"2019","unstructured":"Jackstadt R, van Hooff SR, Leach JD, Cortes-Lavaud X, Lohuis JO, Ridgway RA, et al. Epithelial NOTCH signaling rewires the tumor microenvironment of colorectal cancer to drive Poor-Prognosis subtypes and metastasis. Cancer Cell. 2019;36:319\u2013e336317.","journal-title":"Cancer Cell"},{"key":"2555_CR18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1186\/s12967-025-06282-z","volume":"23","author":"J Sun","year":"2025","unstructured":"Sun J, Chen Y, Xu Z, Wang W, Li P. Notch signaling in the tumor immune microenvironment of colorectal cancer: mechanisms and therapeutic opportunities. J Transl Med. 2025;23:315.","journal-title":"J Transl Med"},{"key":"2555_CR19","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1515\/jtim-2024-0020","volume":"12","author":"Q Shi","year":"2024","unstructured":"Shi Q, Jiang S, Zeng Y, Yuan X, Zhang Y, Chu Q, et al. A Notch signaling pathway-related gene signature: characterizing the immune microenvironment and predicting prognosis in hepatocellular carcinoma. J Transl Int Med. 2024;12:553\u201368.","journal-title":"J Transl Int Med"},{"key":"2555_CR20","doi-asserted-by":"publisher","first-page":"114248","DOI":"10.1016\/j.biopha.2023.114248","volume":"159","author":"H Zhang","year":"2023","unstructured":"Zhang H, Yang Y, Li X, Yuan X, Chu Q. Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancer. Biomed Pharmacother. 2023;159:114248.","journal-title":"Biomed Pharmacother"},{"key":"2555_CR21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175217","author":"SY Ku","year":"2024","unstructured":"Ku SY, Wang Y, Garcia MM, Yamada Y, Mizuno K, Long MD, et al. Notch signaling suppresses neuroendocrine differentiation and alters the immune microenvironment in advanced prostate cancer. J Clin Invest. 2024. https:\/\/doi.org\/10.1172\/JCI175217.","journal-title":"J Clin Invest"},{"key":"2555_CR22","doi-asserted-by":"crossref","unstructured":"D\u2019Assoro AB, Leon-Ferre R, Braune EB, Lendahl U. Roles of Notch signaling in the tumor microenvironment. Int J Mol Sci. 2022;23.","DOI":"10.3390\/ijms23116241"},{"key":"2555_CR23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41573-020-00091-3","volume":"20","author":"S Majumder","year":"2021","unstructured":"Majumder S, Crabtree JS, Golde TE, Minter LM, Osborne BA, Miele L. Targeting notch in oncology: the path forward. Nat Rev Drug Discov. 2021;20:125\u201344.","journal-title":"Nat Rev Drug Discov"},{"key":"2555_CR24","doi-asserted-by":"publisher","first-page":"1567040","DOI":"10.3389\/fimmu.2025.1567040","volume":"16","author":"RZ Nie","year":"2025","unstructured":"Nie RZ, Wang H, Wang SS, Chen C, Luo HM, Zhang HK, et al. The role of Notch signaling pathway and non-coding RNAs in cancer and inflammation: progress, therapeutic insights, and future directions. Front Immunol. 2025;16:1567040.","journal-title":"Front Immunol"},{"key":"2555_CR25","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/s41580-025-00835-2","volume":"26","author":"SJ Bray","year":"2025","unstructured":"Bray SJ, Bigas A. Modes of notch signalling in development and disease. Nat Rev Mol Cell Biol. 2025;26:522\u201337.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2555_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.canlet.2019.07.012","volume":"461","author":"BM Krishna","year":"2019","unstructured":"Krishna BM, Jana S, Singhal J, Horne D, Awasthi S, Salgia R, et al. Notch signaling in breast cancer: from pathway analysis to therapy. Cancer Lett. 2019;461:123\u201331.","journal-title":"Cancer Lett"},{"key":"2555_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241210280","author":"L Deshotels","year":"2023","unstructured":"Deshotels L, Safa FM, Saba NS. NOTCH signaling in mantle cell lymphoma: biological and clinical implications. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241210280.","journal-title":"Int J Mol Sci"},{"key":"2555_CR28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1146\/annurev-biophys-101920-082204","volume":"50","author":"D Sprinzak","year":"2021","unstructured":"Sprinzak D, Blacklow SC. Biophysics of Notch signaling. Annu Rev Biophys. 2021;50:157\u201389.","journal-title":"Annu Rev Biophys"},{"key":"2555_CR29","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/23716","volume":"400","author":"A Apelqvist","year":"1999","unstructured":"Apelqvist A, Li H, Sommer L, Beatus P, Anderson DJ, Honjo T, et al. Notch signalling controls pancreatic cell differentiation. Nature. 1999;400:877\u201381.","journal-title":"Nature"},{"key":"2555_CR30","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1158\/2159-8290.CD-14-0650","volume":"5","author":"T Kangsamaksin","year":"2015","unstructured":"Kangsamaksin T, Murtomaki A, Kofler NM, Cuervo H, Chaudhri RA, Tattersall IW, et al. NOTCH decoys that selectively block DLL\/NOTCH or JAG\/NOTCH disrupt angiogenesis by unique mechanisms to inhibit tumor growth. Cancer Discov. 2015;5:182\u201397.","journal-title":"Cancer Discov"},{"key":"2555_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41392-022-00934-y","volume":"7","author":"B Zhou","year":"2022","unstructured":"Zhou B, Lin W, Long Y, Yang Y, Zhang H, Wu K, et al. Notch signaling pathway: architecture, disease, and therapeutics. Signal Transduct Target Ther. 2022;7:95.","journal-title":"Signal Transduct Target Ther"},{"key":"2555_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1542967","volume":"13","author":"C Chen","year":"2025","unstructured":"Chen C, Du Y, Nie R, Wang S, Wang H, Li P. Notch signaling in cancers: mechanism and potential therapy. Front Cell Dev Biol. 2025;13:1542967.","journal-title":"Front Cell Dev Biol"},{"key":"2555_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2024.101041","volume":"57","author":"K Yao","year":"2024","unstructured":"Yao K, Zhan XY, Feng M, Yang KF, Zhou MS, Jia H. Furin, ADAM, and \u03b3-secretase: core regulatory targets in the Notch pathway and the therapeutic potential for breast cancer. Neoplasia. 2024;57:101041.","journal-title":"Neoplasia"},{"key":"2555_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/biom14040480","author":"S Wang","year":"2024","unstructured":"Wang S, Gu S, Chen J, Yuan Z, Liang P, Cui H. Mechanism of notch signaling pathway in malignant progression of glioblastoma and targeted therapy. Biomolecules. 2024. https:\/\/doi.org\/10.3390\/biom14040480.","journal-title":"Biomolecules"},{"key":"2555_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1535-7163.MCT-22-0243","volume":"22","author":"WK You","year":"2023","unstructured":"You WK, Schuetz TJ, Lee SH. Targeting the DLL\/Notch signaling pathway in cancer: challenges and advances in clinical development. Mol Cancer Ther. 2023;22:3\u201311.","journal-title":"Mol Cancer Ther"},{"key":"2555_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-025-02626-z","volume":"30","author":"L Fu","year":"2025","unstructured":"Fu L, Gu X, Lou N, Li J, Xue C. Current research of the Notch pathway in hepatocellular carcinoma. Eur J Med Res. 2025;30:402.","journal-title":"Eur J Med Res"},{"key":"2555_CR37","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/sj.emboj.7600996","volume":"25","author":"A Vacca","year":"2006","unstructured":"Vacca A, Felli MP, Palermo R, Di Mario G, Calce A, Di Giovine M, et al. Notch3 and pre-TCR interaction unveils distinct NF-kappaB pathways in T-cell development and leukemia. Embo J. 2006;25:1000\u20138.","journal-title":"Embo J"},{"key":"2555_CR38","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.tips.2023.09.011","volume":"44","author":"E Medina","year":"2023","unstructured":"Medina E, Perez DH, Antfolk D, Luca VC. New tricks for an old pathway: emerging Notch-based biotechnologies and therapeutics. Trends Pharmacol Sci. 2023;44:934\u201348.","journal-title":"Trends Pharmacol Sci"},{"key":"2555_CR39","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3389\/fonc.2018.00267","volume":"8","author":"V Sosa Iglesias","year":"2018","unstructured":"Sosa Iglesias V, Giuranno L, Dubois LJ, Theys J, Vooijs M. Drug resistance in Non-Small cell lung cancer: a potential for NOTCH targeting? Front Oncol. 2018;8:267.","journal-title":"Front Oncol"},{"key":"2555_CR40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1083\/jcb.200804030","volume":"183","author":"X Wang","year":"2008","unstructured":"Wang X, Pasolli HA, Williams T, Fuchs E. AP-2 factors act in concert with Notch to orchestrate terminal differentiation in skin epidermis. J Cell Biol. 2008;183:37\u201348.","journal-title":"J Cell Biol"},{"key":"2555_CR41","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.ccell.2018.07.009","volume":"34","author":"O Meurette","year":"2018","unstructured":"Meurette O, Mehlen P. Notch signaling in the tumor microenvironment. Cancer Cell. 2018;34:536\u201348.","journal-title":"Cancer Cell"},{"key":"2555_CR42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cac2.12392","volume":"43","author":"Z Fang","year":"2023","unstructured":"Fang Z, Meng Q, Xu J, Wang W, Zhang B, Liu J, et al. Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives. Cancer Commun (Lond). 2023;43:3\u201341.","journal-title":"Cancer Commun (Lond)"},{"key":"2555_CR43","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41392-024-01828-x","volume":"9","author":"Q Shi","year":"2024","unstructured":"Shi Q, Xue C, Zeng Y, Yuan X, Chu Q, Jiang S, et al. Notch signaling pathway in cancer: from mechanistic insights to targeted therapies. Signal Transduct Target Ther. 2024;9:128.","journal-title":"Signal Transduct Target Ther"},{"key":"2555_CR44","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2024.5710","author":"Y Sun","year":"2025","unstructured":"Sun Y, Weng X, Chen W, Ge J, Ding B, Ru J, et al. MYBBP1A\u2011mediated IGFBP4 promoter methylation promotes epithelial\u2011mesenchymal transition and metastasis through activation of NOTCH pathway in liver cancer. Int J Oncol. 2025. https:\/\/doi.org\/10.3892\/ijo.2024.5710.","journal-title":"Int J Oncol"},{"key":"2555_CR45","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41419-025-07470-x","volume":"16","author":"B Yan","year":"2025","unstructured":"Yan B, Lu Q, Gao T, Xiao K, Zong Q, Lv H, et al. CD146 regulates the stemness and chemoresistance of hepatocellular carcinoma via JAG2-NOTCH signaling. Cell Death Dis. 2025;16:150.","journal-title":"Cell Death Dis"},{"key":"2555_CR46","doi-asserted-by":"publisher","first-page":"e2405758","DOI":"10.1002\/advs.202405758","volume":"12","author":"Z Xiang","year":"2025","unstructured":"Xiang Z, Wang Y, Ma X, Song S, He Y, Zhou J, et al. Targeting the NOTCH2\/ADAM10\/TCF7L2 Axis-Mediated transcriptional regulation of Wnt pathway suppresses tumor growth and enhances chemosensitivity in colorectal cancer. Adv Sci (Weinh). 2025;12:e2405758.","journal-title":"Adv Sci (Weinh)"},{"key":"2555_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07110-w","volume":"15","author":"Q Jia","year":"2024","unstructured":"Jia Q, Zhu Y, Yao H, Yin Y, Duan Z, Zheng J, et al. Oncogenic GALNT5 confers FOLFIRINOX resistance via activating the MYH9\/ NOTCH\/ DDR axis in pancreatic ductal adenocarcinoma. Cell Death Dis. 2024;15:767.","journal-title":"Cell Death Dis"},{"key":"2555_CR48","doi-asserted-by":"publisher","first-page":"1658679","DOI":"10.3389\/fimmu.2025.1658679","volume":"16","author":"X Feng","year":"2025","unstructured":"Feng X, Shi Y, Yuan F, Hu Y, Tang X, Zhang W, et al. CRTC1 enhances PD-L1-mediated tumor immunosuppression in non-small cell lung cancer via the Notch1\/Akt signaling pathway. Front Immunol. 2025;16:1658679.","journal-title":"Front Immunol"},{"key":"2555_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01632-8","volume":"22","author":"L Devitt","year":"2024","unstructured":"Devitt L, Westphal D, Pieger K, Schneider N, Bosserhoff AK, Kuphal S. NRN1 interacts with Notch to increase oncogenic STAT3 signaling in melanoma. Cell Commun Signal. 2024;22:256.","journal-title":"Cell Commun Signal"},{"key":"2555_CR50","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1101\/gad.1484707","volume":"21","author":"K Lefort","year":"2007","unstructured":"Lefort K, Mandinova A, Ostano P, Kolev V, Calpini V, Kolfschoten I, et al. Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1\/2 and MRCKalpha kinases. Genes Dev. 2007;21:562\u201377.","journal-title":"Genes Dev"},{"key":"2555_CR51","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk8958","volume":"10","author":"J Ma","year":"2024","unstructured":"Ma J, Gong Y, Sun X, Liu C, Li X, Sun Y, et al. Tumor suppressor FRMD3 controls mammary epithelial cell fate determination via notch signaling pathway. Sci Adv. 2024;10:eadk8958.","journal-title":"Sci Adv"},{"key":"2555_CR52","first-page":"3200","volume":"61","author":"V Sriuranpong","year":"2001","unstructured":"Sriuranpong V, Borges MW, Ravi RK, Arnold DR, Nelkin BD, Baylin SB, et al. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res. 2001;61:3200\u20135.","journal-title":"Cancer Res"},{"key":"2555_CR53","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/ng1099","volume":"33","author":"M Nicolas","year":"2003","unstructured":"Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort M, et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet. 2003;33:416\u201321.","journal-title":"Nat Genet"},{"key":"2555_CR54","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ccr.2009.05.016","volume":"16","author":"S Demehri","year":"2009","unstructured":"Demehri S, Turkoz A, Kopan R. Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment. Cancer Cell. 2009;16:55\u201366.","journal-title":"Cancer Cell"},{"key":"2555_CR55","doi-asserted-by":"publisher","first-page":"e18485","DOI":"10.7717\/peerj.18485","volume":"12","author":"J Roosma","year":"2024","unstructured":"Roosma J. A comprehensive review of oncogenic Notch signaling in multiple myeloma. PeerJ. 2024;12:e18485.","journal-title":"PeerJ"},{"key":"2555_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2025.149761","volume":"969","author":"RS Sidhu","year":"2025","unstructured":"Sidhu RS, Guo S, Wang G, Liu M. Role of Notch and its oncogenic signaling crosstalk in glioma and glioma stem cells. Gene. 2025;969:149761.","journal-title":"Gene"},{"key":"2555_CR57","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.ijbiomac.2022.09.203","volume":"222","author":"M Hashemi","year":"2022","unstructured":"Hashemi M, Hasani S, Hajimazdarany S, Mirmazloomi SR, Makvandy S, Zabihi A, et al. Non-coding RNAs targeting notch signaling pathway in cancer: from proliferation to cancer therapy resistance. Int J Biol Macromol. 2022;222:1151\u201367.","journal-title":"Int J Biol Macromol"},{"key":"2555_CR58","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1038\/s41375-024-02331-6","volume":"38","author":"H Kim","year":"2024","unstructured":"Kim H, Tan TK, Lee DZY, Huang XZ, Ong JZL, Kelliher MA, et al. Oncogenic dependency on SWI\/SNF chromatin remodeling factors in T-cell acute lymphoblastic leukemia. Leukemia. 2024;38:1906\u201317.","journal-title":"Leukemia"},{"key":"2555_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2025.105939","volume":"165","author":"S Gupta","year":"2025","unstructured":"Gupta S, Dasari S, Shen W, Kipp BR, Erickson LA, Cheville JC. Insights from single cell and bulk RNA sequencing: increased NOTCH signaling is correlated with oncogenic transformation of juxtaglomerular cells to juxtaglomerular cell tumors. Hum Pathol. 2025;165:105939.","journal-title":"Hum Pathol"},{"key":"2555_CR60","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10792-025-03449-x","volume":"45","author":"J Chen","year":"2025","unstructured":"Chen J, Zeng B. METTL14-mediated m(6)A modification of LINC00340 exerts oncogenic role in retinoblastoma by regulating Notch signaling pathway. Int Ophthalmol. 2025;45:73.","journal-title":"Int Ophthalmol"},{"key":"2555_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2025.101549","volume":"19","author":"L Qiao","year":"2025","unstructured":"Qiao L, Hu Y, Xu L, Deng G, Yu X, Zheng W, et al. Unraveling the oncogenic characteristics of the cytolinker, plectin, in esophageal squamous cell carcinoma. Cell Mol Gastroenterol Hepatol. 2025;19:101549.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2555_CR62","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s43018-025-00964-9","volume":"6","author":"A Beck","year":"2025","unstructured":"Beck A, Gabler-Pamer L, Alencastro Veiga Cruzeiro G, Lambo S, Englinger B, Shaw ML, et al. Cellular hierarchies of embryonal tumors with multilayered rosettes are shaped by oncogenic MicroRNAs and receptor-ligand interactions. Nat Cancer. 2025;6:1035\u201355.","journal-title":"Nat Cancer"},{"key":"2555_CR63","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41585-018-0005-1","volume":"15","author":"A Goriki","year":"2018","unstructured":"Goriki A, Seiler R, Wyatt AW, Contreras-Sanz A, Bhat A, Matsubara A, et al. Unravelling disparate roles of NOTCH in bladder cancer. Nat Rev Urol. 2018;15:345\u201357.","journal-title":"Nat Rev Urol"},{"key":"2555_CR64","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1158\/2159-8290.CD-RW2014-195","volume":"4","author":"The NOTCH pathway","year":"2014","unstructured":"The NOTCH pathway. Plays a tumor suppressive role in bladder cancer. Cancer Discov. 2014;4:1252.","journal-title":"Cancer Discov"},{"key":"2555_CR65","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1158\/0008-5472.CAN-22-0076","volume":"82","author":"E Alsina-Sanchis","year":"2022","unstructured":"Alsina-Sanchis E, M\u00fclfarth R, Moll I, B\u00f6hn S, Wiedmann L, Jordana-Urriza L, et al. Endothelial RBPJ is essential for the education of Tumor-Associated macrophages. Cancer Res. 2022;82:4414\u201328.","journal-title":"Cancer Res"},{"key":"2555_CR66","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1158\/0008-5472.CAN-18-1691","volume":"79","author":"YC Ye","year":"2019","unstructured":"Ye YC, Zhao JL, Lu YT, Gao CC, Yang Y, Liang SQ, et al. NOTCH signaling via WNT regulates the proliferation of alternative, CCR2-independent tumor-associated macrophages in hepatocellular carcinoma. Cancer Res. 2019;79:4160\u201372.","journal-title":"Cancer Res"},{"key":"2555_CR67","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/2326-6066.CIR-23-0037","volume":"12","author":"W Yan","year":"2024","unstructured":"Yan W, Menjivar RE, Bonilla ME, Steele NG, Kemp SB, Du W, et al. Notch signaling regulates immunosuppressive Tumor-Associated macrophage function in pancreatic cancer. Cancer Immunol Res. 2024;12:91\u2013106.","journal-title":"Cancer Immunol Res"},{"key":"2555_CR68","doi-asserted-by":"publisher","first-page":"goab052","DOI":"10.1093\/gastro\/goab052","volume":"10","author":"JB Ye","year":"2022","unstructured":"Ye JB, Wen JJ, Wu DL, Hu BX, Luo MQ, Lin YQ, et al. Elevated DLL3 in stomach cancer by tumor-associated macrophages enhances cancer-cell proliferation and cytokine secretion of macrophages. Gastroenterol Rep (Oxf). 2022;10:goab052.","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"2555_CR69","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1016\/j.cmet.2024.05.013","volume":"36","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Wang Y, Chen G, Sun F, Wu Q, Huang Q, et al. Nicotinamide metabolism face-off between macrophages and fibroblasts manipulates the microenvironment in gastric cancer. Cell Metab. 2024;36:1806\u2013e18221811.","journal-title":"Cell Metab"},{"key":"2555_CR70","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.immuni.2024.03.020","volume":"57","author":"JK Mandula","year":"2024","unstructured":"Mandula JK, Sierra-Mondragon RA, Jimenez RV, Chang D, Mohamed E, Chang S, et al. Jagged2 targeting in lung cancer activates anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophages. Immunity. 2024;57:1124\u2013e11401129.","journal-title":"Immunity"},{"key":"2555_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15092295","author":"H Liu","year":"2023","unstructured":"Liu H, He R, Yang X, Huang B, Liu H. Mechanism of TCF21 downregulation leading to immunosuppression of tumor-associated macrophages in non-small cell lung cancer. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15092295.","journal-title":"Pharmaceutics"},{"key":"2555_CR72","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13046-020-01676-x","volume":"39","author":"S Tao","year":"2020","unstructured":"Tao S, Chen Q, Lin C, Dong H. Linc00514 promotes breast cancer metastasis and M2 polarization of tumor-associated macrophages via Jagged1-mediated Notch signaling pathway. J Exp Clin Cancer Res. 2020;39:191.","journal-title":"J Exp Clin Cancer Res"},{"key":"2555_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00437-8","volume":"6","author":"YH Huang","year":"2021","unstructured":"Huang YH, Cai K, Xu PP, Wang L, Huang CX, Fang Y, et al. CREBBP\/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2\/CSF1 axis. Signal Transduct Target Ther. 2021;6:10.","journal-title":"Signal Transduct Target Ther"},{"key":"2555_CR74","doi-asserted-by":"publisher","first-page":"216807","DOI":"10.1016\/j.canlet.2024.216807","volume":"593","author":"H Lin","year":"2024","unstructured":"Lin H, Fu L, Zhou X, Yu A, Chen Y, Liao W, et al. LRP1 induces anti-PD-1 resistance by modulating the DLL4-NOTCH2-CCL2 axis and redirecting M2-like macrophage polarisation in bladder cancer. Cancer Lett. 2024;593:216807.","journal-title":"Cancer Lett"},{"key":"2555_CR75","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/cac2.70021","volume":"45","author":"C Wang","year":"2025","unstructured":"Wang C, Yang M, Zhong Y, Cao K, Wang X, Zhang C, et al. Immunosuppressive JAG2(+) tumor-associated neutrophils hamper PD-1 blockade response in ovarian cancer by mediating the differentiation of effector regulatory T cells. Cancer Commun (Lond). 2025;45:747\u201373.","journal-title":"Cancer Commun (Lond)"},{"key":"2555_CR76","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1038\/s41416-020-1026-0","volume":"123","author":"M Yang","year":"2020","unstructured":"Yang M, Zhang G, Wang Y, He M, Xu Q, Lu J, et al. Tumour-associated neutrophils orchestrate intratumoural IL-8-driven immune evasion through Jagged2 activation in ovarian cancer. Br J Cancer. 2020;123:1404\u201316.","journal-title":"Br J Cancer"},{"key":"2555_CR77","doi-asserted-by":"publisher","first-page":"1470620","DOI":"10.3389\/fimmu.2024.1470620","volume":"15","author":"J Dimitrov","year":"2024","unstructured":"Dimitrov J, Maddalena M, Terlizzi C, Altobelli GG, Pellegrino S, Mehmood T, et al. Dynamic roles of neutrophil extracellular traps in cancer cell adhesion and activation of Notch 1-mediated epithelial-to-mesenchymal transition in EGFR-driven lung cancer cells. Front Immunol. 2024;15:1470620.","journal-title":"Front Immunol"},{"key":"2555_CR78","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ccell.2019.08.010","volume":"36","author":"J Ruland","year":"2019","unstructured":"Ruland J. Colon cancer: epithelial notch signaling recruits neutrophils to drive metastasis. Cancer Cell. 2019;36:213\u20134.","journal-title":"Cancer Cell"},{"key":"2555_CR79","doi-asserted-by":"publisher","first-page":"110451","DOI":"10.1016\/j.celrep.2022.110451","volume":"38","author":"JL Zhao","year":"2022","unstructured":"Zhao JL, Ye YC, Gao CC, Wang L, Ren KX, Jiang R, et al. Notch-mediated lactate metabolism regulates MDSC development through the Hes1\/MCT2\/c-Jun axis. Cell Rep. 2022;38:110451.","journal-title":"Cell Rep"},{"key":"2555_CR80","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejca.2016.08.019","volume":"68","author":"SH Wang","year":"2016","unstructured":"Wang SH, Lu QY, Guo YH, Song YY, Liu PJ, Wang YC. The blockage of notch signalling promoted the generation of polymorphonuclear myeloid-derived suppressor cells with lower immunosuppression. Eur J Cancer. 2016;68:90\u2013105.","journal-title":"Eur J Cancer"},{"key":"2555_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25189882","author":"B Abdollahzadeh","year":"2024","unstructured":"Abdollahzadeh B, Cantale Aeo NM, Giordano N, Orlando A, Basciani M, Peruzzi G, et al. The NF-\u03baB1\/p50 subunit influences the notch\/IL-6-driven expansion of myeloid-derived suppressor cells in murine T-cell acute lymphoblastic leukemia. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25189882.","journal-title":"Int J Mol Sci"},{"key":"2555_CR82","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1158\/0008-5472.CAN-15-2528","volume":"76","author":"D Peng","year":"2016","unstructured":"Peng D, Tanikawa T, Li W, Zhao L, Vatan L, Szeliga W, et al. Myeloid-Derived suppressor cells endow Stem-like qualities to breast cancer cells through IL6\/STAT3 and NO\/NOTCH Cross-talk signaling. Cancer Res. 2016;76:3156\u201365.","journal-title":"Cancer Res"},{"key":"2555_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20081916","author":"ML Sprouse","year":"2019","unstructured":"Sprouse ML, Welte T, Boral D, Liu HN, Yin W, Vishnoi M, et al. PMN-MDSCs enhance CTC metastatic properties through reciprocal interactions via ROS\/Notch\/Nodal signaling. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20081916.","journal-title":"Int J Mol Sci"},{"key":"2555_CR84","doi-asserted-by":"publisher","first-page":"5628","DOI":"10.1158\/0008-5472.CAN-17-0357","volume":"77","author":"RA Sierra","year":"2017","unstructured":"Sierra RA, Trillo-Tinoco J, Mohamed E, Yu L, Achyut BR, Arbab A, et al. Anti-Jagged immunotherapy inhibits MDSCs and overcomes tumor-induced tolerance. Cancer Res. 2017;77:5628\u201338.","journal-title":"Cancer Res"},{"key":"2555_CR85","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1476-4598-9-90","volume":"9","author":"F Feng","year":"2010","unstructured":"Feng F, Wang YC, Hu XB, Liu XW, Ji G, Chen YR, et al. The transcription factor RBP-J-mediated signaling is essential for dendritic cells to evoke efficient anti-tumor immune responses in mice. Mol Cancer. 2010;9:90.","journal-title":"Mol Cancer"},{"key":"2555_CR86","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-019-0566-4","volume":"7","author":"EE Tchekneva","year":"2019","unstructured":"Tchekneva EE, Goruganthu MUL, Uzhachenko RV, Thomas PL, Antonucci A, Chekneva I, et al. Determinant roles of dendritic cell-expressed Notch Delta-like and Jagged ligands on anti-tumor T cell immunity. J Immunother Cancer. 2019;7:95.","journal-title":"J Immunother Cancer"},{"key":"2555_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-016-0150-3","volume":"17","author":"XQ Qian","year":"2016","unstructured":"Qian XQ, Chen LL, Cheng Q, Tian Y, Luo XF, Wan XY. Inhibition of notch 1 receptor influenced the differentiation of Lin-CD45RA-dendritic cell precursors within ovarian carcinoma microenvironment. BMC Immunol. 2016;17:14.","journal-title":"BMC Immunol"},{"key":"2555_CR88","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1158\/2326-6066.CIR-20-0428","volume":"9","author":"L Wang","year":"2021","unstructured":"Wang L, Yu S, Chan ER, Chen KY, Liu C, Che D, et al. Notch-Regulated dendritic cells restrain Inflammation-Associated colorectal carcinogenesis. Cancer Immunol Res. 2021;9:348\u201361.","journal-title":"Cancer Immunol Res"},{"key":"2555_CR89","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.yexcr.2016.10.019","volume":"349","author":"X Gao","year":"2016","unstructured":"Gao X, Han D, Fan W. Down-regulation of RBP-J mediated by microRNA-133a suppresses dendritic cells and functions as a potential tumor suppressor in osteosarcoma. Exp Cell Res. 2016;349:264\u201372.","journal-title":"Exp Cell Res"},{"key":"2555_CR90","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1182\/blood-2015-05-644476","volume":"127","author":"K Mochizuki","year":"2016","unstructured":"Mochizuki K, Meng L, Mochizuki I, Tong Q, He S, Liu Y, et al. Programming of donor T cells using allogeneic \u03b4-like ligand 4-positive dendritic cells to reduce GVHD in mice. Blood. 2016;127:3270\u201380.","journal-title":"Blood"},{"key":"2555_CR91","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2020057118","author":"N Zhang","year":"2021","unstructured":"Zhang N, Yin R, Zhou P, Liu X, Fan P, Qian L, et al. Dll1 orchestrates CD8(+) T cells to induce long-term vascular normalization and tumor regression. Proc Natl Acad Sci U S A. 2021. https:\/\/doi.org\/10.1073\/pnas.2020057118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2555_CR92","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.intimp.2018.07.033","volume":"63","author":"S Li","year":"2018","unstructured":"Li S, Wang Z, Li XJ. Notch signaling pathway suppresses CD8(+) T cells activity in patients with lung adenocarcinoma. Int Immunopharmacol. 2018;63:129\u201336.","journal-title":"Int Immunopharmacol"},{"key":"2555_CR93","doi-asserted-by":"publisher","first-page":"18219","DOI":"10.1074\/jbc.M113.475376","volume":"288","author":"G Kong","year":"2013","unstructured":"Kong G, Du J, Liu Y, Meline B, Chang YI, Ranheim EA, et al. Notch1 gene mutations target KRAS G12D-expressing CD8\u2009+\u2009cells and contribute to their leukemogenic transformation. J Biol Chem. 2013;288:18219\u201327.","journal-title":"J Biol Chem"},{"key":"2555_CR94","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.biopha.2017.10.143","volume":"97","author":"W Yu","year":"2018","unstructured":"Yu W, Wang Y, Guo P. Notch signaling pathway dampens tumor-infiltrating CD8(+) T cells activity in patients with colorectal carcinoma. Biomed Pharmacother. 2018;97:535\u201342.","journal-title":"Biomed Pharmacother"},{"key":"2555_CR95","doi-asserted-by":"publisher","first-page":"5330","DOI":"10.7150\/thno.58337","volume":"11","author":"WJ Zhou","year":"2021","unstructured":"Zhou WJ, Zhang J, Xie F, Wu JN, Ye JF, Wang J, et al. CD45RO(-)CD8(+) T cell-derived exosomes restrict estrogen-driven endometrial cancer development via the ER\u03b2\/miR-765\/PLP2\/Notch axis. Theranostics. 2021;11:5330\u201345.","journal-title":"Theranostics"},{"key":"2555_CR96","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1182\/blood.2021015144","volume":"140","author":"AB Wilkens","year":"2022","unstructured":"Wilkens AB, Fulton EC, Pont MJ, Cole GO, Leung I, Stull SM, et al. NOTCH1 signaling during CD4\u2009+\u2009T-cell activation alters transcription factor networks and enhances antigen responsiveness. Blood. 2022;140:2261\u201375.","journal-title":"Blood"},{"key":"2555_CR97","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20182044","author":"L Yang","year":"2019","unstructured":"Yang L, Zhao KL, Qin L, Ji DX, Zhang B, Zheng PF, et al. Notch signaling pathway regulates CD4(+)CD25(+)CD127(dim\/-) regulatory T cells and T helper 17 cells function in gastric cancer patients. Biosci Rep. 2019. https:\/\/doi.org\/10.1042\/BSR20182044.","journal-title":"Biosci Rep"},{"key":"2555_CR98","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20181922","author":"B Pang","year":"2018","unstructured":"Pang B, Hu C, Xing N, Xu L, Zhang S, Yu X. Elevated Notch1 enhances interleukin-22 production by CD4(+) T cells via aryl hydrocarbon receptor in patients with lung adenocarcinoma. Biosci Rep. 2018. https:\/\/doi.org\/10.1042\/BSR20181922.","journal-title":"Biosci Rep"},{"key":"2555_CR99","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41419-021-04471-4","volume":"13","author":"C Zhong","year":"2022","unstructured":"Zhong C, Tao B, Li X, Xiang W, Peng L, Peng T, et al. HOXA-AS2 contributes to regulatory T cell proliferation and immune tolerance in glioma through the miR-302a\/KDM2A\/JAG1 axis. Cell Death Dis. 2022;13:160.","journal-title":"Cell Death Dis"},{"key":"2555_CR100","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.yexmp.2016.04.006","volume":"100","author":"F Ortiz-Mart\u00ednez","year":"2016","unstructured":"Ortiz-Mart\u00ednez F, Guti\u00e9rrez-Avi\u00f1\u00f3 FJ, Sanmart\u00edn E, Pomares-Navarro E, Villalba-Riquelme C, Garc\u00eda-Mart\u00ednez A, et al. Association of Notch pathway down-regulation with triple Negative\/Basal-like breast carcinomas and high tumor-infiltrating FOXP3\u2009+\u2009Tregs. Exp Mol Pathol. 2016;100:460\u20138.","journal-title":"Exp Mol Pathol"},{"key":"2555_CR101","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1128\/JVI.74.4.1727-1735.2000","volume":"74","author":"LJ Strobl","year":"2000","unstructured":"Strobl LJ, H\u00f6felmayr H, Marschall G, Brielmeier M, Bornkamm GW, Zimber-Strobl U. Activated Notch1 modulates gene expression in B cells similarly to Epstein-Barr viral nuclear antigen 2. J Virol. 2000;74:1727\u201335.","journal-title":"J Virol"},{"key":"2555_CR102","doi-asserted-by":"publisher","first-page":"5506","DOI":"10.1182\/blood-2008-11-190090","volume":"113","author":"H Kohlhof","year":"2009","unstructured":"Kohlhof H, Hampel F, Hoffmann R, Burtscher H, Weidle UH, H\u00f6lzel M, et al. Notch1, Notch2, and Epstein-Barr virus-encoded nuclear antigen 2 signaling differentially affects proliferation and survival of Epstein-Barr virus-infected B cells. Blood. 2009;113:5506\u201315.","journal-title":"Blood"},{"key":"2555_CR103","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1038\/leu.2008.101","volume":"22","author":"F Jundt","year":"2008","unstructured":"Jundt F, Acikg\u00f6z O, Kwon SH, Schwarzer R, Anagnostopoulos I, Wiesner B, et al. Aberrant expression of Notch1 interferes with the B-lymphoid phenotype of neoplastic B cells in classical Hodgkin lymphoma. Leukemia. 2008;22:1587\u201394.","journal-title":"Leukemia"},{"key":"2555_CR104","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1182\/bloodadvances.2018019919","volume":"2","author":"H Arima","year":"2018","unstructured":"Arima H, Nishikori M, Otsuka Y, Kishimoto W, Izumi K, Yasuda K, et al. B cells with aberrant activation of Notch1 signaling promote Treg and Th2 cell-dominant T-cell responses via IL-33. Blood Adv. 2018;2:2282\u201395.","journal-title":"Blood Adv"},{"key":"2555_CR105","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41419-020-2355-x","volume":"11","author":"S Li","year":"2020","unstructured":"Li S, Huang C, Hu G, Ma J, Chen Y, Zhang J, et al. Tumor-educated B cells promote renal cancer metastasis via inducing the IL-1\u03b2\/HIF-2\u03b1\/Notch1 signals. Cell Death Dis. 2020;11:163.","journal-title":"Cell Death Dis"},{"key":"2555_CR106","doi-asserted-by":"publisher","first-page":"115708","DOI":"10.1016\/j.celrep.2025.115708","volume":"44","author":"F Yang","year":"2025","unstructured":"Yang F, Li A, Zhu Y, Zhou Y, Tian E, Yang M, et al. GATA1-mediated Notch signaling augment antitumor immunity of CD11b(+)CD27(-) natural killer cells maturation via BCL9\/\u03b2-catenin signal. Cell Rep. 2025;44:115708.","journal-title":"Cell Rep"},{"key":"2555_CR107","doi-asserted-by":"publisher","first-page":"23282","DOI":"10.1038\/s41598-021-02651-y","volume":"11","author":"KH Liang","year":"2021","unstructured":"Liang KH, Chang CC, Wu KS, Yu AL, Sung SY, Lee YY, et al. Notch signaling and natural killer cell infiltration in tumor tissues underlie Medulloblastoma prognosis. Sci Rep. 2021;11:23282.","journal-title":"Sci Rep"},{"key":"2555_CR108","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/ncb3228","volume":"17","author":"MG Procopio","year":"2015","unstructured":"Procopio MG, Laszlo C, Al Labban D, Kim DE, Bordignon P, Jo SH, et al. Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation. Nat Cell Biol. 2015;17:1193\u2013204.","journal-title":"Nat Cell Biol"},{"key":"2555_CR109","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1016\/j.celrep.2017.08.048","volume":"20","author":"S Goruppi","year":"2017","unstructured":"Goruppi S, Procopio MG, Jo S, Clocchiatti A, Neel V, Dotto GP. The ULK3 kinase is critical for convergent control of cancer-associated fibroblast activation by CSL and GLI. Cell Rep. 2017;20:2468\u201379.","journal-title":"Cell Rep"},{"key":"2555_CR110","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1084\/jem.20170724","volume":"214","author":"DE Kim","year":"2017","unstructured":"Kim DE, Procopio MG, Ghosh S, Jo SH, Goruppi S, Magliozzi F, et al. Convergent roles of ATF3 and CSL in chromatin control of cancer-associated fibroblast activation. J Exp Med. 2017;214:2349\u201368.","journal-title":"J Exp Med"},{"key":"2555_CR111","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s41423-022-00930-w","volume":"19","author":"HJ Kim","year":"2022","unstructured":"Kim HJ, Yang K, Kim K, Lee YJ, Lee S, Ahn SY, et al. Reprogramming of cancer-associated fibroblasts by apoptotic cancer cells inhibits lung metastasis via Notch1-WISP-1 signaling. Cell Mol Immunol. 2022;19:1373\u201391.","journal-title":"Cell Mol Immunol"},{"key":"2555_CR112","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1101\/gad.347344.120","volume":"35","author":"B Xue","year":"2021","unstructured":"Xue B, Chuang CH, Prosser HM, Fuziwara CS, Chan C, Sahasrabudhe N, et al. miR-200 deficiency promotes lung cancer metastasis by activating Notch signaling in cancer-associated fibroblasts. Genes Dev. 2021;35:1109\u201322.","journal-title":"Genes Dev"},{"key":"2555_CR113","doi-asserted-by":"publisher","first-page":"154928","DOI":"10.1016\/j.phymed.2023.154928","volume":"123","author":"H Chen","year":"2024","unstructured":"Chen H, Han X, Zhang Y, Wang K, Liu D, Hu Z, et al. Bruceine D suppresses CAF-promoted TNBC metastasis under TNF-\u03b1 stimulation by inhibiting Notch1-Jagged1\/NF-\u03baB(p65) signaling. Phytomedicine. 2024;123:154928.","journal-title":"Phytomedicine"},{"key":"2555_CR114","doi-asserted-by":"crossref","unstructured":"Ye F, Liang Y, Wang J, Song J, Jin Y, Wang L et al. A novel peptide MIB1-223aa encoded by Exosomal circMIB1 from cancer-associated fibroblasts drives triple-negative breast cancer metastasis and stemness via stabilizing MIB1 to activate Notch signaling. J Adv Res. 2025.","DOI":"10.1016\/j.jare.2025.06.023"},{"key":"2555_CR115","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1158\/0008-5472.CAN-21-1225","volume":"82","author":"A Nandi","year":"2022","unstructured":"Nandi A, Debnath R, Nayak A, To TKJ, Thacker G, Reilly M, et al. Dll1-Mediated Notch signaling drives tumor cell Cross-talk with cancer-Associated fibroblasts to promote radioresistance in breast cancer. Cancer Res. 2022;82:3718\u201333.","journal-title":"Cancer Res"},{"key":"2555_CR116","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41467-019-14134-w","volume":"11","author":"F Pelon","year":"2020","unstructured":"Pelon F, Bourachot B, Kieffer Y, Magagna I, Mermet-Meillon F, Bonnet I, et al. Cancer-associated fibroblast heterogeneity in axillary lymph nodes drives metastases in breast cancer through complementary mechanisms. Nat Commun. 2020;11:404.","journal-title":"Nat Commun"},{"key":"2555_CR117","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.devcel.2021.12.020","volume":"57","author":"R Ojha","year":"2022","unstructured":"Ojha R, Tantray I, Rimal S, Mitra S, Cheshier S, Lu B. Regulation of reverse electron transfer at mitochondrial complex I by unconventional Notch action in cancer stem cells. Dev Cell. 2022;57:260-276.e269.","journal-title":"Dev Cell"},{"key":"2555_CR118","doi-asserted-by":"publisher","DOI":"10.3390\/cells9030657","author":"I Cristofaro","year":"2020","unstructured":"Cristofaro I, Alessandrini F, Spinello Z, Guerriero C, Fiore M, Caffarelli E, et al. Cross interaction between M2 muscarinic receptor and Notch1\/EGFR pathway in human glioblastoma cancer stem cells: effects on cell cycle progression and survival. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9030657.","journal-title":"Cells"},{"key":"2555_CR119","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1729299","volume":"9","author":"FA Mansour","year":"2020","unstructured":"Mansour FA, Al-Mazrou A, Al-Mohanna F, Al-Alwan M, Ghebeh H. PD-L1 is overexpressed on breast cancer stem cells through notch3\/mTOR axis. Oncoimmunology. 2020;9:1729299.","journal-title":"Oncoimmunology"},{"key":"2555_CR120","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.matbio.2018.11.007","volume":"81","author":"KS Papadakos","year":"2019","unstructured":"Papadakos KS, Bartoschek M, Rodriguez C, Gialeli C, Jin SB, Lendahl U, et al. Cartilage oligomeric matrix protein initiates cancer stem cells through activation of Jagged1-Notch3 signaling. Matrix Biol. 2019;81:107\u201321.","journal-title":"Matrix Biol"},{"key":"2555_CR121","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1002\/stem.2473","volume":"34","author":"R Barnawi","year":"2016","unstructured":"Barnawi R, Al-Khaldi S, Majed Sleiman G, Sarkar A, Al-Dhfyan A, Al-Mohanna F, et al. Fascin is critical for the maintenance of breast cancer stem cell pool predominantly via the activation of the Notch Self-Renewal pathway. Stem Cells. 2016;34:2799\u2013813.","journal-title":"Stem Cells"},{"key":"2555_CR122","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70203","volume":"28","author":"T Zhang","year":"2024","unstructured":"Zhang T, Lei J, Zheng M, Wen Z, Zhou J. Nitric oxide facilitates the S-nitrosylation and deubiquitination of Notch1 protein to maintain cancer stem cells in human NSCLC. J Cell Mol Med. 2024;28:e70203.","journal-title":"J Cell Mol Med"},{"key":"2555_CR123","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.canlet.2019.12.026","volume":"472","author":"N Wang","year":"2020","unstructured":"Wang N, Li MY, Liu Y, Yu J, Ren J, Zheng Z, et al. ZBP-89 negatively regulates self-renewal of liver cancer stem cells via suppression of Notch1 signaling pathway. Cancer Lett. 2020;472:70\u201380.","journal-title":"Cancer Lett"},{"key":"2555_CR124","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1186\/s13046-019-1508-1","volume":"38","author":"X Wang","year":"2019","unstructured":"Wang X, Wang R, Bai S, Xiong S, Li Y, Liu M, et al. Musashi2 contributes to the maintenance of CD44v6\u2009+\u2009liver cancer stem cells via notch1 signaling pathway. J Exp Clin Cancer Res. 2019;38:505.","journal-title":"J Exp Clin Cancer Res"},{"key":"2555_CR125","doi-asserted-by":"publisher","first-page":"67","DOI":"10.7150\/thno.16752","volume":"7","author":"C Li","year":"2017","unstructured":"Li C, Liu S, Yan R, Han N, Wong KK, Li L. CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer. Theranostics. 2017;7:67\u201380.","journal-title":"Theranostics"},{"key":"2555_CR126","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41392-025-02309-5","volume":"10","author":"C Li","year":"2025","unstructured":"Li C, Wu P, Xie X, Chen X, Chen L, Zhu L, et al. Aberrant Notch-signaling promotes tumor angiogenesis in esophageal squamous-cell carcinoma. Signal Transduct Target Ther. 2025;10:233.","journal-title":"Signal Transduct Target Ther"},{"key":"2555_CR127","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12943-024-01979-z","volume":"23","author":"Z He","year":"2024","unstructured":"He Z, Zhong Y, Regmi P, Lv T, Ma W, Wang J, et al. Exosomal long non-coding RNA TRPM2-AS promotes angiogenesis in gallbladder cancer through interacting with PABPC1 to activate NOTCH1 signaling pathway. Mol Cancer. 2024;23:65.","journal-title":"Mol Cancer"},{"key":"2555_CR128","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/s41419-024-07016-7","volume":"15","author":"HR Ahn","year":"2024","unstructured":"Ahn HR, Kim S, Baek GO, Yoon MG, Kang M, Ng JT, et al. Effect of Sortilin1 on promoting angiogenesis and systemic metastasis in hepatocellular carcinoma via the Notch signaling pathway and CD133. Cell Death Dis. 2024;15:634.","journal-title":"Cell Death Dis"},{"key":"2555_CR129","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1016\/j.gendis.2022.07.006","volume":"10","author":"J Liu","year":"2023","unstructured":"Liu J, Shi Y, Wu M, Zhang F, Xu M, He Z, et al. JAG1 enhances angiogenesis in triple-negative breast cancer through promoting the secretion of Exosomal LncRNA MALAT1. Genes Dis. 2023;10:2167\u201378.","journal-title":"Genes Dis"},{"key":"2555_CR130","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2022.5155","author":"V Ciccone","year":"2022","unstructured":"Ciccone V, Terzuoli E, Ristori E, Filippelli A, Ziche M, Morbidelli L, et al. ALDH1A1 overexpression in melanoma cells promotes tumor angiogenesis by activating the IL\u20118\/Notch signaling cascade. Int J Mol Med. 2022. https:\/\/doi.org\/10.3892\/ijmm.2022.5155.","journal-title":"Int J Mol Med"},{"key":"2555_CR131","doi-asserted-by":"publisher","first-page":"112025","DOI":"10.1016\/j.cellsig.2025.112025","volume":"135","author":"J Qiang","year":"2025","unstructured":"Qiang J, Qiu T, Yang Y, Xu B, Huang H, Li X, et al. ALDH2 inhibits angiogenesis in esophageal squamous cell carcinoma by suppressing the NOTCH1\/PI3K\/Akt signaling pathway. Cell Signal. 2025;135:112025.","journal-title":"Cell Signal"},{"key":"2555_CR132","doi-asserted-by":"publisher","first-page":"154513","DOI":"10.1016\/j.phymed.2022.154513","volume":"108","author":"S Cha","year":"2023","unstructured":"Cha S, Kim HG, Jang H, Lee J, Chao T, Baek NI, et al. Steppogenin suppresses tumor growth and sprouting angiogenesis through Inhibition of HIF-1\u03b1 in tumors and DLL4 activity in the endothelium. Phytomedicine. 2023;108:154513.","journal-title":"Phytomedicine"},{"key":"2555_CR133","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1161\/CIRCRESAHA.124.325494","volume":"136","author":"J Zhang","year":"2025","unstructured":"Zhang J, Zhao JJ, Zhou HD, Chen J, Hong MN, Wang JG, et al. Endothelial KLF15\/VASN axis inhibits angiogenesis via activation of Notch1 signaling. Circ Res. 2025;136:1595\u2013609.","journal-title":"Circ Res"},{"key":"2555_CR134","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41467-023-36409-z","volume":"14","author":"H Lu","year":"2023","unstructured":"Lu H, Yuan P, Ma X, Jiang X, Liu S, Ma C, et al. Angiotensin-converting enzyme inhibitor promotes angiogenesis through Sp1\/Sp3-mediated Inhibition of Notch signaling in male mice. Nat Commun. 2023;14:731.","journal-title":"Nat Commun"},{"key":"2555_CR135","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.1111\/bph.15904","volume":"179","author":"L Fan","year":"2022","unstructured":"Fan L, Liu H, Zhu G, Singh S, Yu Z, Wang S, et al. Caspase-4\/11 is critical for angiogenesis by repressing Notch1 signalling via inhibiting \u03b3-secretase activity. Br J Pharmacol. 2022;179:4809\u201328.","journal-title":"Br J Pharmacol"},{"key":"2555_CR136","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41420-021-00682-y","volume":"7","author":"H Yan","year":"2021","unstructured":"Yan H, Zhu L, Zhang J, Lin Z. Histone demethylase KDM4D Inhibition suppresses renal cancer progression and angiogenesis through JAG1 signaling. Cell Death Discov. 2021;7:284.","journal-title":"Cell Death Discov"},{"key":"2555_CR137","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02325-5","volume":"10","author":"J Xu","year":"2025","unstructured":"Xu J, Ding L, Mei J, Hu Y, Kong X, Dai S, et al. Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments. Signal Transduct Target Ther. 2025;10:268.","journal-title":"Signal Transduct Target Ther"},{"key":"2555_CR138","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-025-03377-9","volume":"44","author":"Y Yang","year":"2025","unstructured":"Yang Y, Li S, To KKW, Zhu S, Wang F, Fu L. Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy. J Exp Clin Cancer Res. 2025;44:145.","journal-title":"J Exp Clin Cancer Res"},{"key":"2555_CR139","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00652","volume":"9","author":"T Palaga","year":"2018","unstructured":"Palaga T, Wongchana W, Kueanjinda P. Notch signaling in macrophages in the context of cancer immunity. Front Immunol. 2018;9:652.","journal-title":"Front Immunol"},{"key":"2555_CR140","doi-asserted-by":"publisher","first-page":"4840","DOI":"10.1158\/0008-5472.CAN-10-0269","volume":"70","author":"YC Wang","year":"2010","unstructured":"Wang YC, He F, Feng F, Liu XW, Dong GY, Qin HY, et al. Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Res. 2010;70:4840\u20139.","journal-title":"Cancer Res"},{"key":"2555_CR141","doi-asserted-by":"publisher","first-page":"4456","DOI":"10.1016\/j.apsb.2025.07.021","volume":"15","author":"AQ Li","year":"2025","unstructured":"Li AQ, Huang F, Talaiti S, Yang X, Bi H, Fang JH. Understanding the complexity of tumor-associated macrophages: druggable and therapeutic insights. Acta Pharm Sin B. 2025;15:4456\u201375.","journal-title":"Acta Pharm Sin B"},{"key":"2555_CR142","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02242-7","volume":"10","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Shen G, Zhou X, Li J. Therapeutic potential of tumor-associated neutrophils: dual role and phenotypic plasticity. Signal Transduct Target Ther. 2025;10:178.","journal-title":"Signal Transduct Target Ther"},{"key":"2555_CR143","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/cac2.70027","volume":"45","author":"W Cai","year":"2025","unstructured":"Cai W, Fan T, Xiao C, Deng Z, Liu Y, Li C, et al. Neutrophils in cancer: at the crucial crossroads of anti-tumor and pro-tumor. Cancer Commun (Lond). 2025;45:888\u2013913.","journal-title":"Cancer Commun (Lond)"},{"key":"2555_CR144","doi-asserted-by":"crossref","unstructured":"Segal J, Cronk J, Ball B, Forbes G, Jackett K, Li K, et al. Parallels in canonical developmental signaling pathways between normal development and the tumor microenvironment. Cold Spring Harb Perspect Med; 2025.","DOI":"10.1101\/cshperspect.a041609"},{"key":"2555_CR145","doi-asserted-by":"publisher","first-page":"5846","DOI":"10.7150\/thno.111096","volume":"15","author":"J Zhang","year":"2025","unstructured":"Zhang J, Miao C, Zhang H. Targeting neutrophil extracellular traps in cancer progression and metastasis. Theranostics. 2025;15:5846\u201369.","journal-title":"Theranostics"},{"key":"2555_CR146","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00731-z","volume":"13","author":"Z Liu","year":"2025","unstructured":"Liu Z, Dou Y, Lu C, Han R, He Y. Neutrophil extracellular traps in tumor metabolism and microenvironment. Biomark Res. 2025;13:12.","journal-title":"Biomark Res"},{"key":"2555_CR147","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02208-3","volume":"24","author":"S He","year":"2025","unstructured":"He S, Zheng L, Qi C. Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy. Mol Cancer. 2025;24:5.","journal-title":"Mol Cancer"},{"key":"2555_CR148","doi-asserted-by":"publisher","first-page":"114693","DOI":"10.1016\/j.intimp.2025.114693","volume":"157","author":"H Shi","year":"2025","unstructured":"Shi H, Zhu Y, Shang K, Tian T, Yin Z, Shi J, et al. The role of Notch signaling in regulating myeloid-derived suppressor cells: implications in cancer and autoimmune diseases. Int Immunopharmacol. 2025;157:114693.","journal-title":"Int Immunopharmacol"},{"key":"2555_CR149","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.809261","volume":"13","author":"P Grazioli","year":"2022","unstructured":"Grazioli P, Orlando A, Giordano N, Noce C, Peruzzi G, Abdollahzadeh B, et al. Notch-signaling deregulation induces myeloid-derived suppressor cells in T-cell acute lymphoblastic leukemia. Front Immunol. 2022;13:809261.","journal-title":"Front Immunol"},{"key":"2555_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.218034","volume":"633","author":"Q Chen","year":"2025","unstructured":"Chen Q, Wang W, He X, Wang C, Guo H, Ou C. Dendritic cells-derived extracellular vesicles in tumourigenesis: from biological roles to clinical implications. Cancer Lett. 2025;633:218034.","journal-title":"Cancer Lett"},{"key":"2555_CR151","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01649","volume":"9","author":"M Janghorban","year":"2018","unstructured":"Janghorban M, Xin L, Rosen JM, Zhang XH. Notch signaling as a regulator of the tumor immune response: to target or not to target? Front Immunol. 2018;9:1649.","journal-title":"Front Immunol"},{"key":"2555_CR152","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nri3445","volume":"13","author":"F Radtke","year":"2013","unstructured":"Radtke F, MacDonald HR, Tacchini-Cottier F. Regulation of innate and adaptive immunity by notch. Nat Rev Immunol. 2013;13:427\u201337.","journal-title":"Nat Rev Immunol"},{"key":"2555_CR153","doi-asserted-by":"publisher","first-page":"7010","DOI":"10.1073\/pnas.0709919105","volume":"105","author":"M Kijima","year":"2008","unstructured":"Kijima M, Yamaguchi T, Ishifune C, Maekawa Y, Koyanagi A, Yagita H, et al. Dendritic cell-mediated NK cell activation is controlled by Jagged2-Notch interaction. Proc Natl Acad Sci U S A. 2008;105:7010\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2555_CR154","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1016\/j.celrep.2016.01.056","volume":"14","author":"AJ Tesone","year":"2016","unstructured":"Tesone AJ, Rutkowski MR, Brencicova E, Svoronos N, Perales-Puchalt A, Stephen TL, et al. Satb1 overexpression drives Tumor-Promoting activities in Cancer-Associated dendritic cells. Cell Rep. 2016;14:1774\u201386.","journal-title":"Cell Rep"},{"key":"2555_CR155","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.4049\/jimmunol.1501310","volume":"196","author":"L Meng","year":"2016","unstructured":"Meng L, Bai Z, He S, Mochizuki K, Liu Y, Purushe J, et al. The Notch ligand DLL4 defines a capability of human dendritic cells in regulating Th1 and Th17 differentiation. J Immunol. 2016;196:1070\u201380.","journal-title":"J Immunol"},{"key":"2555_CR156","doi-asserted-by":"publisher","first-page":"e63613","DOI":"10.1371\/journal.pone.0063613","volume":"8","author":"HM Huang","year":"2013","unstructured":"Huang HM, Hsiao G, Fan CK, Lin CL, Leu SJ, Chiang BL, et al. Notch ligand delta-like 4-pretreated dendritic cells alleviate allergic airway responses by enhancing IL-10 production. PLoS One. 2013;8:e63613.","journal-title":"PLoS One"},{"key":"2555_CR157","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202405182","volume":"11","author":"J Hu","year":"2024","unstructured":"Hu J, Shi Q, Xue C, Wang Q. Berberine protects against hepatocellular carcinoma progression by regulating intrahepatic T cell heterogeneity. Adv Sci (Weinh). 2024;11:e2405182.","journal-title":"Adv Sci (Weinh)"},{"key":"2555_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155608","volume":"129","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zeng Y, Yang W, Wang X, Jiang J. Targeting CD8(+) T cells with natural products for tumor therapy: revealing insights into the mechanisms. Phytomedicine. 2024;129:155608.","journal-title":"Phytomedicine"},{"key":"2555_CR159","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00101","volume":"9","author":"SI Tsukumo","year":"2018","unstructured":"Tsukumo SI, Yasutomo K. Regulation of CD8(+) T cells and antitumor immunity by notch signaling. Front Immunol. 2018;9:101.","journal-title":"Front Immunol"},{"key":"2555_CR160","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/imcb.70002","volume":"103","author":"J O\u2019Hara","year":"2025","unstructured":"O\u2019Hara J, Dakle P, Nguyen MLT, Barugahare A, Bennett TJ, Udupa VA, et al. Notch dependent chromatin remodeling enables Gata3 binding and drives lineage specific CD8(+) T cell function. Immunol Cell Biol. 2025;103:365\u201382.","journal-title":"Immunol Cell Biol"},{"key":"2555_CR161","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/978-1-0716-2938-3_8","volume":"2618","author":"ME Kirkling","year":"2023","unstructured":"Kirkling ME, Reizis B. In vitro generation of murine CD8\u03b1(+) DEC205(+) XCR1(+) cross-presenting dendritic cells from bone marrow-derived hematopoietic progenitors. Methods Mol Biol. 2023;2618:109\u201319.","journal-title":"Methods Mol Biol"},{"key":"2555_CR162","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/stem.1512","volume":"32","author":"I Fernandez","year":"2014","unstructured":"Fernandez I, Ooi TP, Roy K. Generation of functional, antigen-specific CD8\u2009+\u2009human T cells from cord blood stem cells using exogenous Notch and tetramer-TCR signaling. Stem Cells. 2014;32:93\u2013104.","journal-title":"Stem Cells"},{"key":"2555_CR163","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s13046-024-03191-9","volume":"43","author":"Z Li","year":"2024","unstructured":"Li Z, Sun M, Yang R, Wang Z, Zhu Q, Zhang Y, et al. Mediator complex subunit 1 promotes oral squamous cell carcinoma progression by activating MMP9 transcription and suppressing CD8(+) T cell antitumor immunity. J Exp Clin Cancer Res. 2024;43:270.","journal-title":"J Exp Clin Cancer Res"},{"key":"2555_CR164","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-023-04521-x","volume":"6","author":"B Pan","year":"2023","unstructured":"Pan B, Wang Z, Zhang X, Shen S, Ke X, Qiu J, et al. Targeted inhibition of RBPJ transcription complex alleviates the exhaustion of CD8(+) T cells in hepatocellular carcinoma. Commun Biol. 2023;6:123.","journal-title":"Commun Biol"},{"key":"2555_CR165","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3389\/fimmu.2017.00320","volume":"8","author":"K Dai","year":"2017","unstructured":"Dai K, Huang L, Huang YB, Chen ZB, Yang LH, Jiang YA. 1810011o10 Rik inhibits the antitumor effect of intratumoral CD8(+) T cells through suppression of Notch2 pathway in a murine hepatocellular carcinoma model. Front Immunol. 2017;8:320.","journal-title":"Front Immunol"},{"key":"2555_CR166","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.bbrc.2014.04.003","volume":"447","author":"Y Haji","year":"2014","unstructured":"Haji Y, Suzuki M, Moriya K, So T, Hozumi K, Mizuma M, et al. Activation of Notch1 promotes development of human CD8(+) single positive T cells in humanized mice. Biochem Biophys Res Commun. 2014;447:346\u201351.","journal-title":"Biochem Biophys Res Commun"},{"key":"2555_CR167","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1186\/s12964-024-01990-3","volume":"22","author":"ZX Wu","year":"2024","unstructured":"Wu ZX, Da TT, Huang C, Wang XQ, Li L, Zhao ZB, et al. CD69(+)CD103(+)CD8(+) tissue-resident memory T cells possess stronger anti-tumor activity and predict better prognosis in colorectal cancer. Cell Commun Signal. 2024;22:608.","journal-title":"Cell Commun Signal"},{"key":"2555_CR168","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01471-y","volume":"8","author":"L Sun","year":"2023","unstructured":"Sun L, Su Y, Jiao A, Wang X, Zhang B. T cells in health and disease. Signal Transduct Target Ther. 2023;8:235.","journal-title":"Signal Transduct Target Ther"},{"key":"2555_CR169","doi-asserted-by":"publisher","first-page":"10476","DOI":"10.1074\/jbc.M709643200","volume":"283","author":"KL Kathrein","year":"2008","unstructured":"Kathrein KL, Chari S, Winandy S. Ikaros directly represses the Notch target gene Hes1 in a leukemia T cell line: implications for CD4 regulation. J Biol Chem. 2008;283:10476\u201384.","journal-title":"J Biol Chem"},{"key":"2555_CR170","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1089\/scd.2008.0021","volume":"18","author":"B Dai","year":"2009","unstructured":"Dai B, Wang P. In vitro differentiation of adult bone marrow progenitors into antigen-specific CD4 helper T cells using engineered stromal cells expressing a Notch ligand and a major histocompatibility complex class II protein. Stem Cells Dev. 2009;18:235\u201345.","journal-title":"Stem Cells Dev"},{"key":"2555_CR171","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/ni.2454","volume":"13","author":"G Le Friec","year":"2012","unstructured":"Le Friec G, Sheppard D, Whiteman P, Karsten CM, Shamoun SA, Laing A, et al. The CD46-Jagged1 interaction is critical for human TH1 immunity. Nat Immunol. 2012;13:1213\u201321.","journal-title":"Nat Immunol"},{"key":"2555_CR172","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.immuni.2014.12.027","volume":"42","author":"K Laky","year":"2015","unstructured":"Laky K, Evans S, Perez-Diez A, Fowlkes BJ. Notch signaling regulates antigen sensitivity of Naive CD4\u2009+\u2009T cells by tuning co-stimulation. Immunity. 2015;42:80\u201394.","journal-title":"Immunity"},{"key":"2555_CR173","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.it.2024.02.005","volume":"45","author":"M Guo","year":"2024","unstructured":"Guo M, Liu MYR, Brooks DG. Regulation and impact of tumor-specific CD4(+) t cells in cancer and immunotherapy. Trends Immunol. 2024;45:303\u201313.","journal-title":"Trends Immunol"},{"key":"2555_CR174","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s43018-023-00521-2","volume":"4","author":"DE Speiser","year":"2023","unstructured":"Speiser DE, Chijioke O, Schaeuble K, M\u00fcnz C. CD4(+) t cells in cancer. Nat Cancer. 2023;4:317\u201329.","journal-title":"Nat Cancer"},{"key":"2555_CR175","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1581093","volume":"16","author":"L Zheng","year":"2025","unstructured":"Zheng L, Wu D, Xie H, Zhao H. Revisiting tregs in cancer and beyond: immunological control and therapeutic potential. Front Immunol. 2025;16:1581093.","journal-title":"Front Immunol"},{"key":"2555_CR176","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.3389\/fimmu.2018.02165","volume":"9","author":"F Ferrandino","year":"2018","unstructured":"Ferrandino F, Grazioli P, Bellavia D, Campese AF, Screpanti I, Felli MP. Notch and NF-\u03baB: coach and players of regulatory T-cell response in cancer. Front Immunol. 2018;9:2165.","journal-title":"Front Immunol"},{"key":"2555_CR177","doi-asserted-by":"publisher","first-page":"107034","DOI":"10.1016\/j.imlet.2025.107034","volume":"276","author":"A Bahabayi","year":"2025","unstructured":"Bahabayi A, Zheng M, Hasimu A, Kang R, Li Q, Xiong Z, et al. Attenuated Notch signaling decreases T-cell factor-1\u2009+\u2009Treg subsets in lung adenocarcinoma, assisting early patient screening. Immunol Lett. 2025;276:107034.","journal-title":"Immunol Lett"},{"key":"2555_CR178","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ccell.2023.02.017","volume":"41","author":"CM Laumont","year":"2023","unstructured":"Laumont CM, Nelson BH. B cells in the tumor microenvironment: multi-faceted organizers, regulators, and effectors of anti-tumor immunity. Cancer Cell. 2023;41:466\u201389.","journal-title":"Cancer Cell"},{"key":"2555_CR179","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1146\/annurev-immunol-101220-015603","volume":"40","author":"SM Downs-Canner","year":"2022","unstructured":"Downs-Canner SM, Meier J, Vincent BG, Serody JS. B cell function in the tumor microenvironment. Annu Rev Immunol. 2022;40:169\u201393.","journal-title":"Annu Rev Immunol"},{"key":"2555_CR180","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S1084-9521(02)00182-9","volume":"14","author":"Y He","year":"2003","unstructured":"He Y, Pear WS. Notch signalling in B cells. Semin Cell Dev Biol. 2003;14:135\u201342.","journal-title":"Semin Cell Dev Biol"},{"key":"2555_CR181","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S1074-7613(02)00271-6","volume":"16","author":"DJ Izon","year":"2002","unstructured":"Izon DJ, Aster JC, He Y, Weng A, Karnell FG, Patriub V, et al. Deltex1 redirects lymphoid progenitors to the B cell lineage by antagonizing Notch1. Immunity. 2002;16:231\u201343.","journal-title":"Immunity"},{"key":"2555_CR182","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1002\/eji.200636325","volume":"36","author":"S Carotta","year":"2006","unstructured":"Carotta S, Brady J, Wu L, Nutt SL. Transient Notch signaling induces NK cell potential in Pax5-deficient pro-B cells. Eur J Immunol. 2006;36:3294\u2013304.","journal-title":"Eur J Immunol"},{"key":"2555_CR183","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1084\/jem.20132100","volume":"212","author":"J Ungerb\u00e4ck","year":"2015","unstructured":"Ungerb\u00e4ck J, \u00c5hsberg J, Strid T, Somasundaram R, Sigvardsson M. Combined heterozygous loss of Ebf1 and Pax5 allows for T-lineage conversion of B cell progenitors. J Exp Med. 2015;212:1109\u201323.","journal-title":"J Exp Med"},{"key":"2555_CR184","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00716-18","author":"CD Wood","year":"2018","unstructured":"Wood CD, Carvell T, Gunnell A, Ojeniyi OO, Osborne C, West MJ. Enhancer control of MicroRNA miR-155 expression in Epstein-Barr virus-infected B cells. J Virol. 2018. https:\/\/doi.org\/10.1128\/JVI.00716-18.","journal-title":"J Virol"},{"key":"2555_CR185","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.159924","author":"J Jakubikova","year":"2023","unstructured":"Jakubikova J, Cholujova D, Beke G, Hideshima T, Klucar L, Leiba M, et al. Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma. JCI Insight. 2023. https:\/\/doi.org\/10.1172\/jci.insight.159924.","journal-title":"JCI Insight"},{"key":"2555_CR186","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03980-y","volume":"25","author":"W Zhu","year":"2025","unstructured":"Zhu W, Fan C, Zhao Y, Li W, Niu J, Dong S, et al. The role of NK cells in regulating tumorimmunity: current state, challenges and future strategies. Cancer Cell Int. 2025;25:360.","journal-title":"Cancer Cell Int"},{"key":"2555_CR187","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.ccell.2024.08.011","volume":"42","author":"L Cords","year":"2024","unstructured":"Cords L, de Souza N, Bodenmiller B. Classifying cancer-associated fibroblasts-the good, the bad, and the target. Cancer Cell. 2024;42:1480\u20135.","journal-title":"Cancer Cell"},{"key":"2555_CR188","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01688-0","volume":"18","author":"H Jia","year":"2025","unstructured":"Jia H, Chen X, Zhang L, Chen M. Cancer associated fibroblasts in cancer development and therapy. J Hematol Oncol. 2025;18:36.","journal-title":"J Hematol Oncol"},{"key":"2555_CR189","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01851-y","volume":"9","author":"X Chu","year":"2024","unstructured":"Chu X, Tian W, Ning J, Xiao G, Zhou Y, Wang Z, et al. Cancer stem cells: advances in knowledge and implications for cancer therapy. Signal Transduct Target Ther. 2024;9:170.","journal-title":"Signal Transduct Target Ther"},{"key":"2555_CR190","doi-asserted-by":"publisher","DOI":"10.3390\/life15020228","author":"S Iluta","year":"2025","unstructured":"Iluta S, Nistor M, Buruiana S, Dima D. Notch and hedgehog signaling unveiled: crosstalk, roles, and breakthroughs in cancer stem cell research. Life. 2025. https:\/\/doi.org\/10.3390\/life15020228.","journal-title":"Life"},{"key":"2555_CR191","doi-asserted-by":"publisher","DOI":"10.3390\/cells10010106","author":"Y Yu","year":"2021","unstructured":"Yu Y, Kim H, Choi S, Yu J, Lee JY, Lee H, et al. Targeting a lipid desaturation enzyme, SCD1, selectively eliminates colon cancer stem cells through the suppression of Wnt and NOTCH signaling. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10010106.","journal-title":"Cells"},{"key":"2555_CR192","doi-asserted-by":"publisher","DOI":"10.2174\/0118761429290933240408071812","volume":"17","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Hu Y, Yang C, Huang S, Wen J, Huang W, et al. Progress of angiogenesis signal pathway and antiangiogenic drugs in nasopharyngeal carcinoma. Curr Mol Pharmacol. 2024;17:e18761429290933.","journal-title":"Curr Mol Pharmacol"},{"key":"2555_CR193","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-024-07698-1","volume":"632","author":"X Pan","year":"2024","unstructured":"Pan X, Li X, Dong L, Liu T, Zhang M, Zhang L, et al. Tumour vasculature at single-cell resolution. Nature. 2024;632:429\u201336.","journal-title":"Nature"},{"key":"2555_CR194","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041166","author":"SS Hasan","year":"2023","unstructured":"Hasan SS, Fischer A. Notch signaling in the vasculature: angiogenesis and angocrine functions. Cold Spring Harb Perspect Med. 2023. https:\/\/doi.org\/10.1101\/cshperspect.a041166.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2555_CR195","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.ijbiomac.2022.09.129","volume":"221","author":"S Vimalraj","year":"2022","unstructured":"Vimalraj S. A concise review of VEGF, PDGF, FGF, Notch, angiopoietin, and HGF signalling in tumor angiogenesis with a focus on alternative approaches and future directions. Int J Biol Macromol. 2022;221:1428\u201338.","journal-title":"Int J Biol Macromol"},{"key":"2555_CR196","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJMoa2210140","volume":"388","author":"M Gounder","year":"2023","unstructured":"Gounder M, Ratan R, Alcindor T, Sch\u00f6ffski P, van der Graaf WT, Wilky BA, et al. Nirogacestat, a \u03b3-secretase inhibitor for desmoid tumors. N Engl J Med. 2023;388:898\u2013912.","journal-title":"N Engl J Med"},{"key":"2555_CR197","doi-asserted-by":"publisher","DOI":"10.1177\/20420986241311461","volume":"16","author":"JM Michot","year":"2025","unstructured":"Michot JM, Balogh Z, Brown JR, Ribrag V, Hollebecque A, Bahleda R, et al. Notch pathway inhibition with crenigacestat (LY3039478) in a phase I first-in-human clinical trial for patients with relapsed or refractory non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia. Ther Adv Drug Saf. 2025;16:20420986241311461.","journal-title":"Ther Adv Drug Saf"},{"key":"2555_CR198","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s10637-019-00739-x","volume":"38","author":"C Even","year":"2020","unstructured":"Even C, Lassen U, Merchan J, Le Tourneau C, Soria JC, Ferte C, et al. Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma. Invest New Drugs. 2020;38:402\u20139.","journal-title":"Invest New Drugs"},{"key":"2555_CR199","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00280-022-04461-z","volume":"90","author":"C Massard","year":"2022","unstructured":"Massard C, Cassier PA, Azaro A, Anderson B, Yuen E, Yu D, et al. A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors. Cancer Chemother Pharmacol. 2022;90:335\u201344.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2555_CR200","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00214-y","volume":"5","author":"AS Mansfield","year":"2021","unstructured":"Mansfield AS, Hong DS, Hann CL, Farago AF, Beltran H, Waqar SN, et al. A phase I\/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. NPJ Precis Oncol. 2021;5:74.","journal-title":"NPJ Precis Oncol"},{"key":"2555_CR201","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.jtho.2021.02.009","volume":"16","author":"F Blackhall","year":"2021","unstructured":"Blackhall F, Jao K, Greillier L, Cho BC, Penkov K, Reguart N, et al. Efficacy and safety of rovalpituzumab Tesirine compared with Topotecan as Second-Line therapy in DLL3-High SCLC: results from the phase 3 TAHOE study. J Thorac Oncol. 2021;16:1547\u201358.","journal-title":"J Thorac Oncol"},{"key":"2555_CR202","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-19-1133","volume":"25","author":"D Morgensztern","year":"2019","unstructured":"Morgensztern D, Besse B, Greillier L, Santana-Davila R, Ready N, Hann CL, et al. Efficacy and safety of rovalpituzumab Tesirine in Third-Line and beyond patients with DLL3-Expressing, Relapsed\/Refractory Small-Cell lung cancer: results from the phase II TRINITY study. Clin Cancer Res. 2019;25:6958\u201366.","journal-title":"Clin Cancer Res"},{"key":"2555_CR203","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","volume":"18","author":"CM Rudin","year":"2017","unstructured":"Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017;18:42\u201351.","journal-title":"Lancet Oncol"},{"key":"2555_CR204","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/j.jtho.2021.02.022","volume":"16","author":"J Malhotra","year":"2021","unstructured":"Malhotra J, Nikolinakos P, Leal T, Lehman J, Morgensztern D, Patel JD, et al. A phase 1\u20132 study of rovalpituzumab Tesirine in combination with nivolumab plus or minus ipilimumab in patients with previously treated Extensive-Stage SCLC. J Thorac Oncol. 2021;16:1559\u201369.","journal-title":"J Thorac Oncol"},{"key":"2555_CR205","doi-asserted-by":"crossref","unstructured":"Ku SY, Manzar N, Garcia MM, Kim MJ, Einstein DJ, Balk SP et al. Preclinical activity of the DLL3-targeted T cell engager MK-6070 in neuroendocrine prostate cancer. Mol Cancer Ther. 2025.","DOI":"10.1158\/1535-7163.c.8289928"},{"key":"2555_CR206","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1158\/1078-0432.CCR-25-1211","volume":"31","author":"R Aggarwal","year":"2025","unstructured":"Aggarwal R, Rottey S, Bernard-Tessier A, Mellado B, Kosaka T, Stadler WM, et al. Safety and efficacy of Tarlatamab in patients with neuroendocrine prostate cancer: results from the phase 1b DeLLpro-300 study. Clin Cancer Res. 2025;31:3854\u201363.","journal-title":"Clin Cancer Res"},{"key":"2555_CR207","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","volume":"389","author":"MJ Ahn","year":"2023","unstructured":"Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, et al. Tarlatamab for patients with previously treated Small-Cell lung cancer. N Engl J Med. 2023;389:2063\u201375.","journal-title":"N Engl J Med"},{"key":"2555_CR208","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1056\/NEJMoa2502099","volume":"393","author":"G Mountzios","year":"2025","unstructured":"Mountzios G, Sun L, Cho BC, Demirci U, Baka S, G\u00fcm\u00fc\u015f M, et al. Tarlatamab in Small-Cell lung cancer after Platinum-Based chemotherapy. N Engl J Med. 2025;393:349\u201361.","journal-title":"N Engl J Med"},{"key":"2555_CR209","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/S1470-2045(25)00480-2","volume":"26","author":"KG Paulson","year":"2025","unstructured":"Paulson KG, Lau SCM, Ahn MJ, Moskovitz M, Pogorzelski M, H\u00e4fliger S, et al. Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study. Lancet Oncol. 2025;26:1300\u201311.","journal-title":"Lancet Oncol"},{"key":"2555_CR210","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1093\/annonc\/mdy171","volume":"29","author":"R Ferrarotto","year":"2018","unstructured":"Ferrarotto R, Eckhardt G, Patnaik A, LoRusso P, Faoro L, Heymach JV, et al. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Ann Oncol. 2018;29:1561\u20138.","journal-title":"Ann Oncol"},{"key":"2555_CR211","doi-asserted-by":"publisher","first-page":"5148","DOI":"10.1002\/cam4.2425","volume":"8","author":"ZI Hu","year":"2019","unstructured":"Hu ZI, Bendell JC, Bullock A, LoConte NK, Hatoum H, Ritch P, et al. A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. Cancer Med. 2019;8:5148\u201357.","journal-title":"Cancer Med"},{"key":"2555_CR212","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s10637-018-0714-6","volume":"37","author":"DC Smith","year":"2019","unstructured":"Smith DC, Chugh R, Patnaik A, Papadopoulos KP, Wang M, Kapoun AM, et al. A phase 1 dose escalation and expansion study of tarextumab (OMP-59R5) in patients with solid tumors. Invest New Drugs. 2019;37:722\u201330.","journal-title":"Invest New Drugs"},{"key":"2555_CR213","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1158\/2767-9764.CRC-23-0333","volume":"3","author":"GJ Hanna","year":"2023","unstructured":"Hanna GJ, Stathis A, Lopez-Miranda E, Racca F, Quon D, Leyvraz S, et al. A phase I study of the Pan-Notch inhibitor CB-103 for patients with advanced adenoid cystic carcinoma and other tumors. Cancer Res Commun. 2023;3:1853\u201361.","journal-title":"Cancer Res Commun"},{"key":"2555_CR214","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41594-024-01439-8","volume":"32","author":"X Guo","year":"2025","unstructured":"Guo X, Li H, Lu X, Liu H, U K, Yan C, et al. Structural basis of human \u03b3-secretase Inhibition by anticancer clinical compounds. Nat Struct Mol Biol. 2025;32:719\u201328.","journal-title":"Nat Struct Mol Biol"},{"key":"2555_CR215","doi-asserted-by":"publisher","first-page":"115991","DOI":"10.1016\/j.bcp.2023.115991","volume":"220","author":"M Feng","year":"2024","unstructured":"Feng M, Santhanam RK, Xing H, Zhou M, Jia H. Inhibition of \u03b3-secretase\/Notch pathway as a potential therapy for reversing cancer drug resistance. Biochem Pharmacol. 2024;220:115991.","journal-title":"Biochem Pharmacol"},{"key":"2555_CR216","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ygyno.2015.03.005","volume":"137","author":"I Diaz-Padilla","year":"2015","unstructured":"Diaz-Padilla I, Wilson MK, Clarke BA, Hirte HW, Welch SA, Mackay HJ, et al. A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia. Gynecol Oncol. 2015;137:216\u201322.","journal-title":"Gynecol Oncol"},{"key":"2555_CR217","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/bjc.2014.497","volume":"111","author":"I Brana","year":"2014","unstructured":"Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, et al. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br J Cancer. 2014;111:1932\u201344.","journal-title":"Br J Cancer"},{"key":"2555_CR218","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1007\/s10637-018-0597-6","volume":"36","author":"KL Aung","year":"2018","unstructured":"Aung KL, El-Khoueiry AB, Gelmon K, Tran B, Bajaj G, He B, et al. A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours. Invest New Drugs. 2018;36:1026\u201336.","journal-title":"Invest New Drugs"},{"key":"2555_CR219","doi-asserted-by":"publisher","first-page":"1637671","DOI":"10.3389\/fnagi.2025.1637671","volume":"17","author":"G Ning","year":"2025","unstructured":"Ning G, Fan X, Juan D, Wenxue Z, Sijia W, Meinei C, et al. The manipulator behind scissors: \u03b3 -secretase and its modulators in alzheimer\u2019s disease. Front Aging Neurosci. 2025;17:1637671.","journal-title":"Front Aging Neurosci"},{"key":"2555_CR220","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cell.2020.11.049","volume":"184","author":"G Yang","year":"2021","unstructured":"Yang G, Zhou R, Guo X, Yan C, Lei J, Shi Y. Structural basis of \u03b3-secretase inhibition and modulation by small molecule drugs. Cell. 2021;184:521-e533514.","journal-title":"Cell"},{"key":"2555_CR221","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s12276-022-00754-8","volume":"54","author":"JY Hur","year":"2022","unstructured":"Hur JY. \u03b3-Secretase in alzheimer\u2019s disease. Exp Mol Med. 2022;54:433\u201346.","journal-title":"Exp Mol Med"},{"key":"2555_CR222","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau6246","author":"RA Habets","year":"2019","unstructured":"Habets RA, de Bock CE, Serneels L, Lodewijckx I, Verbeke D, Nittner D, et al. Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition. Sci Transl Med. 2019. https:\/\/doi.org\/10.1126\/scitranslmed.aau6246.","journal-title":"Sci Transl Med"},{"key":"2555_CR223","doi-asserted-by":"publisher","first-page":"e298","DOI":"10.1002\/onco.13595","volume":"26","author":"P L\u00f3pez-Nieva","year":"2021","unstructured":"L\u00f3pez-Nieva P, Gonz\u00e1lez-S\u00e1nchez L, Cobos-Fern\u00e1ndez M, C\u00f3rdoba R, Santos J, Fern\u00e1ndez-Piqueras J. More insights on the use of \u03b3-secretase inhibitors in cancer treatment. Oncologist. 2021;26:e298-305.","journal-title":"Oncologist"},{"key":"2555_CR224","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrd.2017.227","volume":"17","author":"PJ Carter","year":"2018","unstructured":"Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the \u2018high-hanging fruit\u2019. Nat Rev Drug Discov. 2018;17:197\u2013223.","journal-title":"Nat Rev Drug Discov"},{"key":"2555_CR225","doi-asserted-by":"publisher","first-page":"302ra136","DOI":"10.1126\/scitranslmed.aac9459","volume":"7","author":"LR Saunders","year":"2015","unstructured":"Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015;7:302ra136.","journal-title":"Sci Transl Med"},{"key":"2555_CR226","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.jtho.2021.06.022","volume":"16","author":"CL Hann","year":"2021","unstructured":"Hann CL, Burns TF, Dowlati A, Morgensztern D, Ward PJ, Koch MM, et al. A phase 1 study evaluating rovalpituzumab tesirine in frontline treatment of patients with extensive-stage SCLC. J Thorac Oncol. 2021;16:1582\u20138.","journal-title":"J Thorac Oncol"},{"key":"2555_CR227","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05568-y","volume":"22","author":"S Lin","year":"2024","unstructured":"Lin S, Zhang Y, Yao J, Yang J, Qiu Y, Zhu Z, et al. DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase i inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models. J Transl Med. 2024;22:766.","journal-title":"J Transl Med"},{"key":"2555_CR228","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1200\/JCO.22.02823","volume":"41","author":"L Paz-Ares","year":"2023","unstructured":"Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, et al. Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase i study. J Clin Oncol. 2023;41:2893\u2013903.","journal-title":"J Clin Oncol"},{"key":"2555_CR229","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40265-024-02070-z","volume":"84","author":"S Dhillon","year":"2024","unstructured":"Dhillon S. Tarlatamab: first approval. Drugs. 2024;84:995\u20131003.","journal-title":"Drugs"},{"key":"2555_CR230","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.cell.2009.03.045","volume":"137","author":"R Kopan","year":"2009","unstructured":"Kopan R, Ilagan MX. The canonical notch signaling pathway: unfolding the activation mechanism. Cell. 2009;137:216\u201333.","journal-title":"Cell"},{"key":"2555_CR231","doi-asserted-by":"publisher","first-page":"16292","DOI":"10.1073\/pnas.1922606117","volume":"117","author":"R Lehal","year":"2020","unstructured":"Lehal R, Zaric J, Vigolo M, Urech C, Frismantas V, Zangger N, et al. Pharmacological disruption of the Notch transcription factor complex. Proc Natl Acad Sci U S A. 2020;117:16292\u2013301.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2555_CR232","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153957","author":"M Vigolo","year":"2023","unstructured":"Vigolo M, Urech C, Lamy S, Monticone G, Zabaleta J, Hossain F, et al. The efficacy of CB-103, a first-in-class transcriptional Notch inhibitor, in preclinical models of breast cancer. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15153957.","journal-title":"Cancers (Basel)"},{"key":"2555_CR233","doi-asserted-by":"publisher","first-page":"217775","DOI":"10.1016\/j.canlet.2025.217775","volume":"626","author":"S Liu","year":"2025","unstructured":"Liu S, Chen H, Gagea M, Federico L, Zhang F, Gomez J, et al. ADAMs contribute to triple negative breast cancer via mTORC1 pathway: targeting ADAM-mTOR axis improves efficacy. Cancer Lett. 2025;626:217775.","journal-title":"Cancer Lett"},{"key":"2555_CR234","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041846","author":"RO Alabi","year":"2021","unstructured":"Alabi RO, Lora J, Celen AB, Maretzky T, Blobel CP. Analysis of the conditions that affect the selective processing of endogenous Notch1 by ADAM10 and ADAM17. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22041846.","journal-title":"Int J Mol Sci"},{"key":"2555_CR235","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.canlet.2015.07.048","volume":"369","author":"X Yuan","year":"2015","unstructured":"Yuan X, Wu H, Xu H, Xiong H, Chu Q, Yu S, et al. Notch signaling: an emerging therapeutic target for cancer treatment. Cancer Lett. 2015;369:20\u20137.","journal-title":"Cancer Lett"},{"key":"2555_CR236","doi-asserted-by":"publisher","first-page":"117343","DOI":"10.1016\/j.lfs.2020.117343","volume":"244","author":"HY Lu","year":"2020","unstructured":"Lu HY, Chu HX, Tan YX, Qin XC, Liu MY, Li JD, et al. Novel ADAM-17 inhibitor ZLDI-8 inhibits the metastasis of hepatocellular carcinoma by reversing epithelial-mesenchymal transition in vitro and in vivo. Life Sci. 2020;244:117343.","journal-title":"Life Sci"},{"issue":"7","key":"2555_CR237","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41419-018-0804-6","volume":"9","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Li D, Jiang Q, Cao S, Sun H, Chai Y, et al. Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells. Cell Death Dis. 2018;9:743.","journal-title":"Cell Death Dis"},{"key":"2555_CR238","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107142","volume":"203","author":"C Xu","year":"2024","unstructured":"Xu C, Gao X, Ren T, Geng H, Yang K, Huang Y, et al. The ADAM17 inhibitor ZLDI-8 sensitized hepatocellular carcinoma cells to sorafenib through Notch1-integrin \u03b2-talk. Pharmacol Res. 2024;203:107142.","journal-title":"Pharmacol Res"},{"key":"2555_CR239","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113365","volume":"143","author":"M Arafat Hossain","year":"2024","unstructured":"Arafat Hossain M. A comprehensive review of immune checkpoint inhibitors for cancer treatment. Int Immunopharmacol. 2024;143:113365.","journal-title":"Int Immunopharmacol"},{"key":"2555_CR240","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","volume":"9","author":"SJ Wang","year":"2023","unstructured":"Wang SJ, Dougan SK, Dougan M. Immune mechanisms of toxicity from checkpoint inhibitors. Trends Cancer. 2023;9:543\u201353.","journal-title":"Trends Cancer"},{"key":"2555_CR241","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"2555_CR242","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.semcancer.2022.12.003","volume":"88","author":"M Oladejo","year":"2023","unstructured":"Oladejo M, Paulishak W, Wood L. Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines. Semin Cancer Biol. 2023;88:81\u201395.","journal-title":"Semin Cancer Biol"},{"key":"2555_CR243","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S0092-8674(05)80055-8","volume":"71","author":"RH Schwartz","year":"1992","unstructured":"Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7\/BB1 in interleukin-2 production and immunotherapy. Cell. 1992;71:1065\u20138.","journal-title":"Cell"},{"key":"2555_CR244","doi-asserted-by":"publisher","first-page":"8372","DOI":"10.1073\/pnas.1533209100","volume":"100","author":"GQ Phan","year":"2003","unstructured":"Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 Blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003;100:8372\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2555_CR245","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.immuni.2018.03.007","volume":"48","author":"SA Patel","year":"2018","unstructured":"Patel SA, Minn AJ. Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies. Immunity. 2018;48:417\u201333.","journal-title":"Immunity"},{"key":"2555_CR246","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s13402-023-00869-8","volume":"47","author":"Q Jiang","year":"2024","unstructured":"Jiang Q, Chen H, Zhou S, Zhu T, Liu W, Wu H, et al. Ubiquilin-4 induces immune escape in gastric cancer by activating the Notch signaling pathway. Cell Oncol (Dordr). 2024;47:303\u201319.","journal-title":"Cell Oncol (Dordr)"},{"key":"2555_CR247","doi-asserted-by":"crossref","unstructured":"Perez DH, Antfolk D, Chang S, Bustos XE, Medina E, Ramadan AA et al. Engineering synthetic agonists for targeted activation of Notch signaling. Nat Chem Biol. 2025.","DOI":"10.1101\/2024.08.06.606897"},{"key":"2555_CR248","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13058-025-02045-2","volume":"27","author":"Y Gao","year":"2025","unstructured":"Gao Y, Zuo L, Zheng Y, Sun K, Gao Y, Xu X, et al. NOTCH1 Inhibition enhances immunogenicity and sensitizes triple-negative breast cancer to immune checkpoint inhibitors. Breast Cancer Res. 2025;27:92.","journal-title":"Breast Cancer Res"},{"key":"2555_CR249","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13058-018-0960-8","volume":"20","author":"RM Cabrera","year":"2018","unstructured":"Cabrera RM, Mao SPH, Surve CR, Condeelis JS, Segall JE. A novel neuregulin - jagged1 paracrine loop in breast cancer transendothelial migration. Breast Cancer Res. 2018;20:24.","journal-title":"Breast Cancer Res"},{"key":"2555_CR250","doi-asserted-by":"publisher","first-page":"110492","DOI":"10.1016\/j.celrep.2022.110492","volume":"38","author":"J Meng","year":"2022","unstructured":"Meng J, Jiang YZ, Zhao S, Tao Y, Zhang T, Wang X, et al. Tumor-derived Jagged1 promotes cancer progression through immune evasion. Cell Rep. 2022;38:110492.","journal-title":"Cell Rep"},{"key":"2555_CR251","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/imr.12774","volume":"290","author":"E Jacoby","year":"2019","unstructured":"Jacoby E, Shahani SA, Shah NN. Updates on CAR t-cell therapy in B-cell malignancies. Immunol Rev. 2019;290:39\u201359.","journal-title":"Immunol Rev"},{"key":"2555_CR252","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361\u20135.","journal-title":"Science"},{"key":"2555_CR253","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/d41573-022-00095-1","volume":"21","author":"AR Saez-Iba\u00f1ez","year":"2022","unstructured":"Saez-Iba\u00f1ez AR, Upadhaya S, Partridge T, Shah M, Correa D, Campbell J. Landscape of cancer cell therapies: trends and real-world data. Nat Rev Drug Discov. 2022;21:631\u20132.","journal-title":"Nat Rev Drug Discov"},{"key":"2555_CR254","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","volume":"164","author":"KT Roybal","year":"2016","unstructured":"Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, et al. Precision tumor recognition by T cells with combinatorial Antigen-Sensing circuits. Cell. 2016;164:770\u20139.","journal-title":"Cell"},{"key":"2555_CR255","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221988","author":"MY Lin","year":"2024","unstructured":"Lin MY, Nam E, Shih RM, Shafer A, Bouren A, Ayala Ceja M, et al. Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy. J Exp Med. 2024. https:\/\/doi.org\/10.1084\/jem.20221988.","journal-title":"J Exp Med"},{"key":"2555_CR256","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17:147\u201367.","journal-title":"Nat Rev Clin Oncol"},{"key":"2555_CR257","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110416","volume":"129","author":"MX Xiu","year":"2020","unstructured":"Xiu MX, Liu YM, Kuang BH. The oncogenic role of Jagged1\/Notch signaling in cancer. Biomed Pharmacother. 2020;129:110416.","journal-title":"Biomed Pharmacother"},{"key":"2555_CR258","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nature15715","volume":"528","author":"D Lafkas","year":"2015","unstructured":"Lafkas D, Shelton A, Chiu C, de Leon Boenig G, Chen Y, Stawicki SS, et al. Therapeutic antibodies reveal Notch control of transdifferentiation in the adult lung. Nature. 2015;528:127\u201331.","journal-title":"Nature"},{"key":"2555_CR259","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1158\/1535-7163.MCT-18-1176","volume":"18","author":"M Masiero","year":"2019","unstructured":"Masiero M, Li D, Whiteman P, Bentley C, Greig J, Hassanali T, et al. Development of therapeutic Anti-JAGGED1 antibodies for cancer therapy. Mol Cancer Ther. 2019;18:2030\u201342.","journal-title":"Mol Cancer Ther"},{"key":"2555_CR260","doi-asserted-by":"publisher","DOI":"10.3390\/biom13030459","author":"G Silva","year":"2023","unstructured":"Silva G, Rodrigues AF, Ferreira S, Matos C, Eleut\u00e9rio RP, Marques G, et al. Novel scFv against Notch ligand JAG1 suitable for development of cell therapies toward JAG1-positive tumors. Biomolecules. 2023. https:\/\/doi.org\/10.3390\/biom13030459.","journal-title":"Biomolecules"},{"key":"2555_CR261","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd8836","author":"A Hyrenius-Wittsten","year":"2021","unstructured":"Hyrenius-Wittsten A, Su Y, Park M, Garcia JM, Alavi J, Perry N, et al. Synnotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Sci Transl Med. 2021. https:\/\/doi.org\/10.1126\/scitranslmed.abd8836.","journal-title":"Sci Transl Med"},{"key":"2555_CR262","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe7378","author":"JH Choe","year":"2021","unstructured":"Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA, et al. Synnotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 2021. https:\/\/doi.org\/10.1126\/scitranslmed.abe7378.","journal-title":"Sci Transl Med"},{"key":"2555_CR263","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009636","author":"J Yan","year":"2024","unstructured":"Yan J, Xie Y, Liu Z, Yang Y, Zhou T. DLL4-targeted CAR-T therapy sensitizes neoadjuvant chemotherapy via eliminating cancer stem cells and reshaping immune microenvironment in HER2(+) breast cancer. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2024-009636.","journal-title":"J Immunother Cancer"},{"key":"2555_CR264","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1126\/science.aar7112","volume":"359","author":"U Sahin","year":"2018","unstructured":"Sahin U, T\u00fcreci \u00d6. Personalized vaccines for cancer immunotherapy. Science. 2018;359:1355\u201360.","journal-title":"Science"},{"key":"2555_CR265","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1021\/cr900048k","volume":"109","author":"C Alvarez-Breckenridge","year":"2009","unstructured":"Alvarez-Breckenridge C, Kaur B, Chiocca EA. Pharmacologic and chemical adjuvants in tumor virotherapy. Chem Rev. 2009;109:3125\u201340.","journal-title":"Chem Rev"},{"key":"2555_CR266","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","volume":"18","author":"PK Bommareddy","year":"2018","unstructured":"Bommareddy PK, Shettigar M, Kaufman HL. Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol. 2018;18:498\u2013513.","journal-title":"Nat Rev Immunol"},{"key":"2555_CR267","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"HL Kaufman","year":"2015","unstructured":"Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14:642\u201362.","journal-title":"Nat Rev Drug Discov"},{"key":"2555_CR268","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","volume":"9","author":"R Ma","year":"2023","unstructured":"Ma R, Li Z, Chiocca EA, Caligiuri MA, Yu J. The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer. 2023;9:122\u201339.","journal-title":"Trends Cancer"},{"key":"2555_CR269","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jaad.2020.01.039","volume":"83","author":"K Haitz","year":"2020","unstructured":"Haitz K, Khosravi H, Lin JY, Menge T, Nambudiri VE. Review of talimogene laherparepvec: a first-in-class oncolytic viral treatment of advanced melanoma. J Am Acad Dermatol. 2020;83:189\u201396.","journal-title":"J Am Acad Dermatol"},{"key":"2555_CR270","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40265-015-0522-7","volume":"76","author":"SL Greig","year":"2016","unstructured":"Greig SL. Talimogene laherparepvec: first global approval. Drugs. 2016;76:147\u201354.","journal-title":"Drugs"},{"key":"2555_CR271","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/sj.gt.3301885","volume":"10","author":"BL Liu","year":"2003","unstructured":"Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10:292\u2013303.","journal-title":"Gene Ther"},{"key":"2555_CR272","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780\u20138.","journal-title":"J Clin Oncol"},{"key":"2555_CR273","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1158\/1078-0432.CCR-19-3420","volume":"26","author":"Y Otani","year":"2020","unstructured":"Otani Y, Yoo JY, Chao S, Liu J, Jaime-Ramirez AC, Lee TJ, et al. Oncolytic HSV-infected glioma cells activate NOTCH in adjacent tumor cells sensitizing tumors to gamma secretase inhibition. Clin Cancer Res. 2020;26:2381\u201392.","journal-title":"Clin Cancer Res"},{"key":"2555_CR274","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1158\/1078-0432.CCR-21-2347","volume":"28","author":"Y Otani","year":"2022","unstructured":"Otani Y, Yoo JY, Lewis CT, Chao S, Swanner J, Shimizu T, et al. NOTCH-Induced MDSC recruitment after oHSV virotherapy in CNS cancer models modulates antitumor immunotherapy. Clin Cancer Res. 2022;28:1460\u201373.","journal-title":"Clin Cancer Res"},{"key":"2555_CR275","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ccell.2018.03.011","volume":"33","author":"SJ Russell","year":"2018","unstructured":"Russell SJ, Barber GN. Oncolytic viruses as antigen-agnostic cancer vaccines. Cancer Cell. 2018;33:599\u2013605.","journal-title":"Cancer Cell"},{"key":"2555_CR276","doi-asserted-by":"publisher","first-page":"149461","DOI":"10.1016\/j.gene.2025.149461","volume":"955","author":"MJ Saadh","year":"2025","unstructured":"Saadh MJ, Omar TM, Ballal S, Mahdi MS, Chahar M, Verma R, et al. Notch signaling and cancer: insights into chemoresistance, immune evasion, and immunotherapy. Gene. 2025;955:149461.","journal-title":"Gene"},{"key":"2555_CR277","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.2174\/0118715303261691231107113548","volume":"24","author":"P Pandey","year":"2024","unstructured":"Pandey P, Khan F, Singh M, Verma A, Kumar H, Mazumder A, et al. Study Deciphering the crucial involvement of Notch signaling pathway in human cancers. Endocr Metab Immune Disord Drug Targets. 2024;24:1241\u201353.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"2555_CR278","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1277076","volume":"11","author":"A Ghosh","year":"2023","unstructured":"Ghosh A, Mitra AK. Metastasis and cancer associated fibroblasts: taking it up a NOTCH. Front Cell Dev Biol. 2023;11:1277076.","journal-title":"Front Cell Dev Biol"},{"key":"2555_CR279","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1567524","volume":"16","author":"H Zhang","year":"2025","unstructured":"Zhang H, Hang W, Jing Z, Liu B, Wang X, Li Y, et al. The role of notch signaling pathway in cancer: mechanistic insights, therapeutic potential, and clinical progress. Front Immunol. 2025;16:1567524.","journal-title":"Front Immunol"},{"key":"2555_CR280","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1352484","volume":"15","author":"M Wang","year":"2024","unstructured":"Wang M, Yu F, Zhang Y, Li P. Novel insights into Notch signaling in tumor immunity: potential targets for cancer immunotherapy. Front Immunol. 2024;15:1352484.","journal-title":"Front Immunol"},{"key":"2555_CR281","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/ijc.34629","volume":"153","author":"C Cheng","year":"2023","unstructured":"Cheng C, Zhu G, Li Y, Wang H, Wang S, Li C, et al. Single-cell transcriptome analysis reveals cellular and molecular alterations in small cell lung cancer tumors following chemotherapy. Int J Cancer. 2023;153:1273\u201386.","journal-title":"Int J Cancer"},{"key":"2555_CR282","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1136\/gutjnl-2023-330243","volume":"73","author":"R Li","year":"2024","unstructured":"Li R, Liu X, Huang X, Zhang D, Chen Z, Zhang J, et al. Single-cell transcriptomic analysis Deciphers heterogenous cancer stem-like cells in colorectal cancer and their organ-specific metastasis. Gut. 2024;73:470\u201384.","journal-title":"Gut"},{"key":"2555_CR283","doi-asserted-by":"crossref","unstructured":"Sellers K, Allen TD, Bousamra M 2nd, Tan J, M\u00e9ndez-Lucas A, Lin W, et al. Metabolic reprogramming and Notch activity distinguish between non-small cell lung cancer subtypes. Br J Cancer. 2019;121:51\u201364.","DOI":"10.1038\/s41416-019-0464-z"},{"key":"2555_CR284","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.ajpath.2022.06.008","volume":"192","author":"Y Dou","year":"2022","unstructured":"Dou Y, Pizarro T, Zhou L. Organoids as a model system for studying Notch signaling in intestinal epithelial homeostasis and intestinal cancer. Am J Pathol. 2022;192:1347\u201357.","journal-title":"Am J Pathol"},{"key":"2555_CR285","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1073\/pnas.1214014110","volume":"110","author":"J Izrailit","year":"2013","unstructured":"Izrailit J, Berman HK, Datti A, Wrana JL, Reedijk M. High throughput kinase inhibitor screens reveal TRB3 and MAPK-ERK\/TGF\u03b2 pathways as fundamental Notch regulators in breast cancer. Proc Natl Acad Sci U S A. 2013;110:1714\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2555_CR286","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","volume":"9","author":"Q Guo","year":"2024","unstructured":"Guo Q, Jin Y, Chen X, Ye X, Shen X, Lin M, et al. NF-\u03baB in biology and targeted therapy: new insights and translational implications. Signal Transduct Target Ther. 2024;9:53.","journal-title":"Signal Transduct Target Ther"},{"key":"2555_CR287","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1021\/acsami.4c16278","volume":"17","author":"Y Liu","year":"2025","unstructured":"Liu Y, Zhou Y, Li Y, Kang W, Zhang Y, Xia X, et al. Notch pathway deactivation sensitizes breast cancer stem cells toward chemotherapy using NIR Light-Responsive nanoparticles. ACS Appl Mater Interfaces. 2025;17:430\u201344.","journal-title":"ACS Appl Mater Interfaces"},{"key":"2555_CR288","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1182\/blood-2009-12-253419","volume":"117","author":"S Kannan","year":"2011","unstructured":"Kannan S, Fang W, Song G, Mullighan CG, Hammitt R, McMurray J, et al. Notch\/HES1-mediated PARP1 activation: a cell type-specific mechanism for tumor suppression. Blood. 2011;117:2891\u2013900.","journal-title":"Blood"},{"key":"2555_CR289","doi-asserted-by":"publisher","DOI":"10.3390\/antiox14060657","author":"A Sparaneo","year":"2025","unstructured":"Sparaneo A, Torrisi F, D\u2019Angeli F, Giurdanella G, Bravaccini S, Muscarella LA, et al. Decoding the NRF2-NOTCH crosstalk in lung cancer-an update. Antioxidants (Basel). 2025. https:\/\/doi.org\/10.3390\/antiox14060657.","journal-title":"Antioxidants (Basel)"},{"key":"2555_CR290","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2426742122","volume":"122","author":"K Bertulfo","year":"2025","unstructured":"Bertulfo K, Perez-Duran P, Miller H, Ma C, Ambesi-Impiombato A, Samon J, et al. Therapeutic targeting of the NOTCH1 and neddylation pathways in T cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2025;122:e2426742122.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02555-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02555-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02555-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T11:46:10Z","timestamp":1772451970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-025-02555-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":290,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2555"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02555-9","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The corresponding author has received consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}